prednisolone has been researched along with Sicca Syndrome in 209 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the long-term outcome of autoimmune pancreatitis (AIP) including morphological changes in the pancreas, pancreatic duct, biliary tract, pancreatic function, and changes in the clinical manifestations after oral prednisolone (PSL) therapy." | 7.73 | Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. ( Nishino, T; Oyama, H; Shimizu, K; Shiratori, K; Toki, F, 2006) |
| "Sirolimus is an effective and safe treatment option for refractory CTD-TP patients." | 7.01 | Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. ( Li, M; Wang, Q; Wu, C; Xu, D; Zeng, X, 2021) |
| "Initial dosage of prednisolone was 15." | 6.69 | Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. ( Matoba, K; Miyawaki, S; Nishiyama, S, 1999) |
| "Tacrolimus was discontinued." | 6.48 | Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. ( Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2012) |
| "We report a case of interstitial cystitis (IC) associated with primary Sjögren's syndrome (SS) successfully controlled with combination therapy of tacrolimus and a corticosteroid." | 5.43 | Interstitial cystitis associated with primary Sjögren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review. ( Kaneko, H; Kano, T; Mimori, A; Takahashi, H; Takahashi, Y; Tomoe, H; Ueda, Y; Yamashita, H, 2016) |
| "NK lymphocytosis is rarely associated with autoimmune disease, but the combination of indomethacin and steroid therapy may have a favorable effect for such patients." | 5.34 | Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil. ( Fujii, T; Fujita, Y; Mimori, T; Takeda, N; Tanaka, M, 2007) |
| " A total of 91 patients with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30-60 mg daily) were prospectively enrolled." | 3.88 | Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. ( Kaneko, K; Kawai, S; Kawazoe, M; Kusunoki, N; Nanki, T; Shikano, K, 2018) |
| " Renal tubular acidosis (RTA) was treated with alkali replacement and moderate-severe tubulointerstitial nephritis (TIN) was treated with oral prednisolone." | 3.88 | Renal involvement in primary Sjogren's syndrome: a prospective cohort study. ( Emmanuel, D; Jain, A; Jain, VK; Negi, VS; Parameshwaran, S; Srinivas, BH, 2018) |
| " This condition led to ileus, which was effectively treated using prednisolone." | 3.83 | Multiple Mesenteric Panniculitis as a Complication of Sjögren's Syndrome Leading to Ileus. ( Abe, Y; Egashira, Y; Fujiwara, K; Higuchi, K; Iguchi, M; Inoue, T; Kakimoto, K; Kawakami, K; Kojima, Y; Nouda, S; Okada, T; Takeuchi, T; Toshina, K; Yorifuji, N, 2016) |
| "We investigated the long-term outcome of autoimmune pancreatitis (AIP) including morphological changes in the pancreas, pancreatic duct, biliary tract, pancreatic function, and changes in the clinical manifestations after oral prednisolone (PSL) therapy." | 3.73 | Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. ( Nishino, T; Oyama, H; Shimizu, K; Shiratori, K; Toki, F, 2006) |
| "Sirolimus is an effective and safe treatment option for refractory CTD-TP patients." | 3.01 | Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. ( Li, M; Wang, Q; Wu, C; Xu, D; Zeng, X, 2021) |
| "Initial dosage of prednisolone was 15." | 2.69 | Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. ( Matoba, K; Miyawaki, S; Nishiyama, S, 1999) |
| "Despite restarting olanzapine, her visual hallucinations persisted." | 2.50 | Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review. ( Andrews, T; D'Cruz, D; Nortley, R; Wong, JK, 2014) |
| "Tacrolimus was discontinued." | 2.48 | Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. ( Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2012) |
| "Annular erythema has been recognized to be a specific, cutaneous manifestation associated with Sjögren's syndrome." | 2.46 | Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions. ( Katayama, I; Kiyohara, E; Kotobuki, Y; Murota, H, 2010) |
| "We report a case of subacute transverse myelitis associated with Sjögren's syndrome free of xerosis." | 2.41 | [A case of Sjögren's syndrome with subacute transverse myelitis as the initial manifestation]. ( Arai, C; Furutani, R; Ushiyama, M, 2002) |
| "In the first case the bullae decreased in size with corticosteroid treatment." | 2.41 | Two cases of Sjögren's syndrome with multiple bullae. ( Ando, M; Kohrogi, H; Saita, N; Sakamoto, O; Suga, M, 2002) |
| "A diagnosis of transverse myelitis and peripheral neuropathy presenting as neurologic manifestations of SS was made." | 2.40 | [A case of primary Sjögren's syndrome accompanied by transverse myelitis]. ( Aoki, M; Goto, M; Inada, S; Ishii, M; Kaneko, Y; Nakajima, A; Suwa, A; Tanaka, K; Tsutsumino, M; Uehara, T; Yamada, T, 1998) |
| "BOOP has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arthritis (RA), but the association of BOOP and PM has rarely been documented." | 2.39 | Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. ( Imasaki, T; Ishikawa, A; Ogura, T; Takahashi, T; Tanaka, S; Yoshii, A, 1996) |
| " SjS is a relatively rare immune-related adverse event that might sometimes be overlooked." | 1.56 | Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer. ( Furuta, Y; Higashi, T; Miyamoto, H; Nagaoka, K; Naito, H; Nakayama, H; Naoe, H; Tanaka, M; Yoshida, R, 2020) |
| "Investigations revealed distal renal tubular acidosis with severe metabolic bone disease as an extra-glandular manifestation of primary SS." | 1.56 | Primary Sjogren's syndrome manifesting with distal renal tubular acidosis and severe metabolic bone disease. ( Bhandari, S; Jain, G; Kalra, S; Vasnik, G, 2020) |
| "She had been followed up as mixed connective tissue disease and Sjögren's syndrome for over 19 years." | 1.48 | Emergence of Smoldering ANCA-associated Glomerulonephritis during the Clinical Course of Mixed Connective Tissue Disease and Sjögren's Syndrome. ( Asako, K; Fujigaki, Y; Kikuchi, H; Kondo, F; Kono, H; Morimoto, C; Ota, T; Shibata, S; Tamura, Y; Uchida, S; Yamaguchi, Y, 2018) |
| "Renal biopsy revealed tubulointerstitial nephritis with a mild focal infiltration of lymphocytes and plasma cells." | 1.48 | A Case of Sjögren's Syndrome Complicated with Interstitial Nephritis and Delayed Onset Autoimmune Hepatitis. ( Arai, T; Atsukawa, M; Fukui, M; Itokawa, N; Kashiwagi, T; Shimizu, A; Tsuruoka, S; Yamada, T, 2018) |
| "Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, multisystem disorder." | 1.48 | Sjögren's and plasma cell variant Castleman disease: a case report. ( Abrahams, AD; Dei-Adomakoh, YA; Dey, DI; Quarcoopome, L; Segbefia, CI, 2018) |
| "Primary lymph node plasmacytoma is a rare disease that typically involves lymph nodes of the neck." | 1.46 | Unusual course of generalized lymph node primary plasmacytoma in a patient with Sjögren's syndrome: a case report. ( Gorodetskiy, VR; Probatova, NA; Vasilyev, VI, 2017) |
| "Corticosteroid therapy remains the main treatment for systemic lupus erythematosus." | 1.46 | [Severe Interstitial Lung Disease and Manic Symptoms Secondary to Corticosteroids in a Patient with Systemic Lupus Erythematosus and Secondary Sjögren's Syndrome]. ( Branco, JC; Falcão, S; Pedrosa, T; Serra, SS, 2017) |
| "We report a case of interstitial cystitis (IC) associated with primary Sjögren's syndrome (SS) successfully controlled with combination therapy of tacrolimus and a corticosteroid." | 1.43 | Interstitial cystitis associated with primary Sjögren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review. ( Kaneko, H; Kano, T; Mimori, A; Takahashi, H; Takahashi, Y; Tomoe, H; Ueda, Y; Yamashita, H, 2016) |
| "He was diagnosed with autoimmune hepatitis, polymyositis and Sjögren's syndrome and received combined antiretroviral therapy (cART); however, the laboratory abnormalities persisted." | 1.42 | Corticoid therapy for overlapping syndromes in an HIV-positive patient. ( Higuchi, M; Kaieda, T; Kaku, Y; Kodama, S; Minami, R; Miyamura, T; Nakamura, A; Nakamura, M; Suematsu, E; Takahama, S; Yamamoto, M, 2015) |
| "By 24 months, renal tubular acidosis was improved and the bone density had normalized." | 1.39 | Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. ( Hirata, S; Inokuchi, N; Mori, H; Okada, Y; Saito, K; Tanaka, Y; Yamamoto, S, 2013) |
| "Recurrent parotitis is an acute, severe inflammation of one or both parotid glands, the major salivary glands in young children." | 1.37 | Recurrent parotitis as a first manifestation in a child with primary Sjogren's syndrome. ( Alp, H; Erdogan, T; Gursan, N; Karabag, K; Orbak, Z, 2011) |
| "We report a first case of severe autoimmune hemolytic anemia caused by warm reactive IgM antibodies in primary Sjögren's syndrome." | 1.36 | Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome. ( Hounoki, H; Ogawa, R; Shinoda, K; Sugiyama, E; Taki, H; Tobe, K, 2010) |
| "Glomeruloid hemangioma is a specific marker of POEMS syndrome and is related to Castleman's disease." | 1.35 | Glomeruloid hemangioma. ( Shikata, N; Takasu, K; Tsubura, A; Yamazaki, F; Yuri, T, 2008) |
| "A 54-year-old female was diagnosed as mixed connective tissue disease (MCTD) complicated with secondary Sjögren's syndrome." | 1.35 | A case of mixed connective tissue disease complicated with hypertrophic obstructive cardiomyopathy. ( Ashizawa, N; Eguchi, K; Fukuda, T; Hayashi, T; Ida, H; Kawakami, A; Koide, Y; Nakamura, H; Sasaki, M; Sato, S; Seto, S; Tateishi, S, 2008) |
| "Due to secondary myelofibrosis accompanied by Sjögren syndrome, she was started on prednisolone (PSL) and recovered completely from the anemia and thrombocytopenia." | 1.34 | [Successful treatment with prednisolone for autoimmune myelofibrosis accompanied with Sjögren syndrome]. ( Hattori, N; Maeda, T; Nakamaki, T; Nakashima, H; Tomoyasu, S; Usui, T; Yanagisawa, K, 2007) |
| "NK lymphocytosis is rarely associated with autoimmune disease, but the combination of indomethacin and steroid therapy may have a favorable effect for such patients." | 1.34 | Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil. ( Fujii, T; Fujita, Y; Mimori, T; Takeda, N; Tanaka, M, 2007) |
| "Sjogren's syndrome and ankylosing spondylitis can occur either alone or in conjunction with other disorders." | 1.33 | Coexisting ankylosing spondylitis and Sjogren's syndrome: a case report. ( Cakirbay, H; Capkin, E; Guler, M; Karkucak, M; Topbas, M; Tosun, M, 2005) |
| "Treatment with prednisolone quickly brought remission of systemic and laryngeal symptoms as well as improvement in the results of video-laryngostroboscopic tests." | 1.33 | Cricoarytenoid arthritis in Sjögren's syndrome. ( Broussolle, C; Bui-Xuan, C; Charhon, A; Poupart, M; Sève, P, 2005) |
| "Pericarditis is seen in half of patients with SSc and rarely with SjS, and is usually asymptomatic." | 1.33 | [A case of systemic sclerosis and Sjogren's syndrome with cardiac tamponade due to steroid-responsive pericarditis]. ( Akiyama, O; Hagiwara, K; Kobayashi, S; Oominami, SY; Sato, T; Souma, T, 2006) |
| "Two were complicated with primary biliary cirrhosis (PBC) and autoimmune thyroiditis, whereas the other was complicated with interstitial pneumonia, but not with either PBC or autoimmune thyroiditis." | 1.33 | [Three patients with nephrotic syndrome due to membranous nephropathy complicated by Sjögren's syndrome]. ( Baba, A; Eto, T; Fujimoto, S; Hara, S; Sato, Y; Yamada, K, 2005) |
| "Severe pulmonary hypertension is one of the fetal complications in various connective tissue diseases." | 1.32 | Severe pulmonary hypertension associated with primary Sjögren's syndrome. ( Ide, H; Kikuchi, K; Nakagawa, N; Nakano, H; Nishigaki, Y; Obata, H; Ohsaki, Y; Osanai, S; Takahashi, S; Tokusashi, Y, 2003) |
| "She was diagnosed as primary biliary cirrhosis (PBC) associated with subclinical Sjögren syndrome (SjS)." | 1.32 | Prurigo pigmentosa in a patient with primary biliary cirrhosis and Sjögren syndrome. ( Shinkai, H; Togawa, Y; Utani, A, 2004) |
| "This case suggests that when severe interstitial cystitis is associated with Sjögren's syndrome, a therapeutic trial of corticosteroids and cyclosporin may be beneficial." | 1.32 | Severe interstitial cystitis associated with Sjögren's syndrome. ( Fujii, A; Hara, S; Hosino, J; Katori, H; Murata, H; Nishi, T; Sawa, N; Shibata, S; Tagami, T; Takaichi, K; Takemoto, F; Ubara, Y; Yokota, M, 2004) |
| "Systemic panniculitis is a rare complication in SS, and the pathogenesis is unclear." | 1.31 | [Case of subcutaneous and mesenteric acute panniculitis with Sjögren's syndrome]. ( Hagiyama, H; Kohsaka, H; Koike, R; Kubota, T; Miyasaka, N; Nagasaka, K; Nanki, T; Nishio, J; Nonomura, Y; Nosaka, Y; Ogawa, J; Sugihara, T, 2002) |
| "Treatment with prednisolone resulted in marked improvement of biochemical, hematological and dermatological abnormalities." | 1.31 | Autoimmune hepatitis concomitant with hypergammaglobulinemic purpura, immune thrombocytopenia, and Sjögren's syndrome. ( Kamimoto, H; Nakasho, K; Park, SY; Shintani, S; Wada, M, 2001) |
| "We report a patient with a myelopathy in primary Sjögren's syndrome, proven by salivary gland biopsy and specific antibodies." | 1.31 | Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. ( Hermisson, M; Klein, R; Küker, W; Schmidt, F; Weller, M, 2002) |
| "She also began to notice dizziness (orthostatic hypotension) during the last 5 years." | 1.30 | [Peripheral neuropathy and dysautonomia in a patient with primary Sjögren's syndrome]. ( Chikazawa, H; Hashimoto, K; Nishiya, K, 1998) |
| "When prednisolone was gradually tapered to the dose of 30 mg per day, she was transferred to our department because of high grade fever and pancytopenia." | 1.30 | [A case of Sjögren's syndrome with retrobulbar optic neuritis and cutaneous vasculitis]. ( Ideguchi, H; Ishigatsubo, Y; Nagaoka, S; Ohkubo, T; Ohno, S; Oketani, M; Sasaki, T; Shirai, A, 1999) |
| "Prednisolone was given (60 m/day), and the symptoms and the abnormality on the chest roentgenogram resolved within about 1 month." | 1.29 | [Primary Sjögren's syndrome accompanied by pleural effusion]. ( Kashiwabara, K; Kiguchi, T; Kishi, K; Kusama, H; Matsuoka, K; Nakamura, H; Narushima, K; Syohda, S; Yagyu, H, 1995) |
| "He had a previous history of selective IgA deficiency and ulcerative colitis treated with sulphasalazine." | 1.29 | Primary Sjögren's syndrome, ulcerative colitis and selective IgA deficiency. ( Colaco, CB; McCrea, DJ; Steuer, A, 1996) |
| "Here we also discuss the treatment of thymoma and the combination of these two diseases." | 1.29 | [Sjögren's syndrome complicated by thymoma]. ( Iwai, Y; Kageshita, T; Kajiura, Y; Matsubara, M; Nakata, H; Nishimura, Y; Terashima, M; Yokoyama, M, 1996) |
| "It was increased in the active cases of systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)." | 1.28 | Serum level of interferon-gamma in autoimmune diseases. ( Funauchi, M; Horiuchi, A; Minoda, M; Sugishima, H, 1991) |
| "Treatment with prednisolone brought relief." | 1.28 | Endobronchial pseudolymphoma associated with Sjögren's syndrome. Report of a case. ( Kajiki, A; Kido, M; Kuroiwa, A; Miyazaki, N; Yamazaki, H; Yoashihara, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (12.92) | 18.7374 |
| 1990's | 46 (22.01) | 18.2507 |
| 2000's | 70 (33.49) | 29.6817 |
| 2010's | 58 (27.75) | 24.3611 |
| 2020's | 8 (3.83) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, Y | 1 |
| Otsuka, Y | 1 |
| Katsuyama, T | 1 |
| Nishimura, Y | 2 |
| Oka, K | 1 |
| Hasegawa, K | 2 |
| Hagiya, H | 2 |
| Otsuka, F | 2 |
| Kamogawa, Y | 1 |
| Akita, K | 1 |
| Sato, H | 1 |
| Shirai, T | 1 |
| Ishii, T | 1 |
| Harigae, H | 1 |
| Fujii, H | 2 |
| Basheer, A | 1 |
| Khan, EA | 1 |
| Hashmi, T | 1 |
| Khan, RA | 1 |
| Ahmad, A | 1 |
| Kodama, T | 1 |
| Yamazaki, Y | 1 |
| Takeo, H | 1 |
| Limaye, VS | 1 |
| Cash, K | 1 |
| Smith, C | 1 |
| Koszyca, B | 1 |
| Patel, S | 1 |
| Greenberg, SA | 1 |
| Hissaria, P | 1 |
| Jain, G | 1 |
| Kalra, S | 1 |
| Vasnik, G | 1 |
| Bhandari, S | 1 |
| Xu, J | 1 |
| Yang, Y | 1 |
| Chen, D | 1 |
| Lu, Z | 1 |
| Ge, J | 1 |
| Li, X | 1 |
| Gao, X | 1 |
| Higashi, T | 1 |
| Miyamoto, H | 1 |
| Yoshida, R | 1 |
| Furuta, Y | 1 |
| Nagaoka, K | 1 |
| Naoe, H | 1 |
| Naito, H | 1 |
| Nakayama, H | 1 |
| Tanaka, M | 3 |
| Iwata, N | 1 |
| Tomiita, M | 1 |
| Kobayashi, I | 1 |
| Inoue, Y | 1 |
| Nonaka, Y | 1 |
| Okamoto, N | 1 |
| Umebayashi, H | 1 |
| Hara, R | 1 |
| Ito, Y | 1 |
| Sato, Y | 3 |
| Mori, M | 1 |
| Wu, C | 1 |
| Wang, Q | 1 |
| Xu, D | 1 |
| Li, M | 1 |
| Zeng, X | 2 |
| Gorodetskiy, VR | 1 |
| Probatova, NA | 1 |
| Vasilyev, VI | 1 |
| Serra, SS | 1 |
| Pedrosa, T | 1 |
| Falcão, S | 1 |
| Branco, JC | 1 |
| Kawazoe, M | 1 |
| Kaneko, K | 1 |
| Shikano, K | 1 |
| Kusunoki, N | 1 |
| Nanki, T | 2 |
| Kawai, S | 1 |
| Koga, Y | 1 |
| Uchiyama Md, K | 1 |
| Tsukamoto Md PhD, N | 1 |
| Shibusawa Md PhD, N | 1 |
| Utsugi Md PhD, M | 1 |
| Kakizaki Md PhD, S | 1 |
| Hirato Md PhD, J | 1 |
| Dobashi Md PhD, K | 1 |
| Hisada Md PhD, T | 1 |
| Yamada Md PhD, M | 1 |
| Tomimatsu, T | 1 |
| Hazama, Y | 1 |
| Takeuchi, M | 1 |
| Kimura, T | 1 |
| Shimoya, K | 1 |
| Chen, FY | 1 |
| Lee, A | 1 |
| Ge, S | 1 |
| Nathan, S | 1 |
| Knox, SM | 1 |
| McNamara, NA | 1 |
| Nakano, Y | 1 |
| Yamamoto, M | 4 |
| Komatsu, K | 1 |
| Yagita, M | 1 |
| Fujita, M | 1 |
| Miyagawa, F | 1 |
| Asada, H | 1 |
| Morimoto, C | 1 |
| Fujigaki, Y | 1 |
| Tamura, Y | 1 |
| Ota, T | 1 |
| Shibata, S | 2 |
| Asako, K | 1 |
| Kikuchi, H | 1 |
| Kono, H | 1 |
| Kondo, F | 1 |
| Yamaguchi, Y | 2 |
| Uchida, S | 1 |
| Fujimoto, S | 4 |
| Kawabata, H | 2 |
| Kurose, N | 2 |
| Kawanami-Iwao, H | 1 |
| Sakai, T | 1 |
| Kawanami, T | 2 |
| Fujita, Y | 2 |
| Fukushima, T | 2 |
| Masaki, Y | 3 |
| Yamada, T | 2 |
| Fukui, M | 1 |
| Kashiwagi, T | 1 |
| Arai, T | 1 |
| Itokawa, N | 1 |
| Atsukawa, M | 1 |
| Shimizu, A | 1 |
| Tsuruoka, S | 1 |
| Dei-Adomakoh, YA | 1 |
| Quarcoopome, L | 1 |
| Abrahams, AD | 1 |
| Segbefia, CI | 1 |
| Dey, DI | 1 |
| Jain, A | 1 |
| Srinivas, BH | 1 |
| Emmanuel, D | 1 |
| Jain, VK | 1 |
| Parameshwaran, S | 1 |
| Negi, VS | 1 |
| Yoshida, T | 1 |
| Kinjo, M | 1 |
| Nakane, S | 1 |
| Agrawal, S | 1 |
| Bharti, V | 1 |
| Jain, MN | 1 |
| Purkar, PD | 1 |
| Verma, A | 1 |
| Deshpande, AK | 1 |
| Triantafyllias, K | 1 |
| Karaiskaki, N | 1 |
| Hansen, T | 1 |
| Galle, PR | 1 |
| Schwarting, A | 1 |
| Oh, HJ | 1 |
| Mok, YM | 1 |
| Baek, MS | 1 |
| Lee, JK | 1 |
| Seo, BS | 1 |
| Kim, TH | 1 |
| Choi, KH | 2 |
| Hwang, IK | 1 |
| Ra, JE | 1 |
| Oh, YR | 1 |
| Kim, YS | 1 |
| Cho, EY | 1 |
| Kim, HC | 1 |
| Sohn, YW | 1 |
| Fegan, D | 1 |
| Glennon, MJ | 1 |
| Takahashi, T | 2 |
| Ueda, Y | 1 |
| Tomoe, H | 1 |
| Takahashi, H | 4 |
| Takahashi, Y | 1 |
| Yamashita, H | 1 |
| Kaneko, H | 1 |
| Kano, T | 1 |
| Mimori, A | 1 |
| Wong, JK | 1 |
| Nortley, R | 1 |
| Andrews, T | 1 |
| D'Cruz, D | 1 |
| Subbarayudu, B | 1 |
| Sharma, MS | 1 |
| Sreemannarayana, P | 1 |
| Lee, WS | 1 |
| Kaku, Y | 1 |
| Kodama, S | 1 |
| Higuchi, M | 1 |
| Nakamura, A | 1 |
| Nakamura, M | 1 |
| Kaieda, T | 1 |
| Takahama, S | 1 |
| Minami, R | 1 |
| Miyamura, T | 1 |
| Suematsu, E | 1 |
| Fujimoto, M | 1 |
| Ikeda, K | 1 |
| Nakamura, T | 3 |
| Iwamoto, T | 1 |
| Furuta, S | 1 |
| Nakajima, H | 2 |
| Waseda, K | 1 |
| Hanayama, Y | 1 |
| Terasaka, T | 1 |
| Kimura, K | 1 |
| Tsuzuki, T | 1 |
| Nada, T | 1 |
| Nakamura, E | 1 |
| Murakami, K | 1 |
| Kondo, E | 1 |
| Justet, A | 1 |
| Ottaviani, S | 1 |
| Dieudé, P | 1 |
| Taillé, C | 1 |
| Liao, CY | 1 |
| Chien, ST | 1 |
| Wang, CC | 1 |
| Chen, IH | 1 |
| Chiu, HW | 1 |
| Liu, MY | 1 |
| Lin, CH | 1 |
| Ben, RJ | 1 |
| Tsai, MK | 1 |
| Sterling, RA | 1 |
| Carlin, A | 1 |
| Takagi, Y | 2 |
| Sumi, M | 1 |
| Nakamura, H | 5 |
| Sato, S | 2 |
| Kawakami, A | 3 |
| Lin, YR | 1 |
| Shih, CC | 1 |
| Chen, HC | 1 |
| Chen, SJ | 1 |
| Kakimoto, K | 1 |
| Inoue, T | 1 |
| Toshina, K | 1 |
| Yorifuji, N | 1 |
| Iguchi, M | 1 |
| Fujiwara, K | 1 |
| Kojima, Y | 1 |
| Okada, T | 1 |
| Nouda, S | 1 |
| Kawakami, K | 1 |
| Abe, Y | 1 |
| Takeuchi, T | 3 |
| Egashira, Y | 1 |
| Higuchi, K | 1 |
| Izumi, Y | 1 |
| Nakaoka, K | 1 |
| Kamata, M | 1 |
| Iwanaga, N | 2 |
| Imadachi, S | 1 |
| Kurohama, H | 1 |
| Ito, M | 1 |
| Migita, K | 1 |
| Kabuto, M | 1 |
| Fujimoto, N | 1 |
| Hamaguchi, Y | 1 |
| Tanaka, T | 1 |
| Nakahara, E | 1 |
| Yagasaki, H | 1 |
| Shimozawa, K | 1 |
| Hirai, M | 1 |
| Takahashi, S | 3 |
| Zahlane, S | 1 |
| Louhab, N | 1 |
| El Mellakh, M | 1 |
| Kissani, N | 1 |
| Nguyen, M | 1 |
| Peschken, CA | 1 |
| Mugundhan, K | 1 |
| Vasif, MC | 1 |
| Prakash, G | 1 |
| Balamurugan, N | 1 |
| Sivakumar, KG | 1 |
| Bakthavatchalam, B | 1 |
| Almeida, RS | 1 |
| Oliveira, AA | 1 |
| Pego, PM | 1 |
| Abuowda, Y | 1 |
| Gaspar, I | 1 |
| Costa, JM | 1 |
| Sasaki, N | 1 |
| Baba, S | 1 |
| Itou, H | 1 |
| Kowada, K | 1 |
| Shikanai, T | 1 |
| Nakamura, Y | 1 |
| Yamauchi, K | 1 |
| Inoue, H | 2 |
| Sawai, T | 1 |
| Dong, L | 1 |
| Kitagawa, K | 1 |
| Morikawa, Y | 1 |
| Shinomura, Y | 1 |
| Imai, K | 3 |
| Saeki, T | 1 |
| Azumi, A | 1 |
| Nakada, S | 1 |
| Sugiyama, E | 3 |
| Matsui, S | 2 |
| Origuchi, T | 2 |
| Nishiyama, S | 3 |
| Nishimori, I | 1 |
| Nojima, T | 1 |
| Yamada, K | 3 |
| Kawano, M | 2 |
| Zen, Y | 1 |
| Kaneko, M | 1 |
| Miyazaki, K | 1 |
| Tsubota, K | 1 |
| Eguchi, K | 4 |
| Tomoda, K | 1 |
| Sawaki, T | 1 |
| Sugai, S | 3 |
| Umehara, H | 1 |
| Min, JH | 1 |
| Youn, YC | 1 |
| Yamauchi, N | 1 |
| Muramatsu, H | 1 |
| Inomata, H | 1 |
| Numata, T | 1 |
| Nozawa, E | 1 |
| Nishino, M | 1 |
| Koyama, R | 1 |
| Ihara, K | 1 |
| Nishisato, T | 1 |
| Hirayama, M | 1 |
| Katsuki, S | 1 |
| Matsunaga, T | 1 |
| Niitsu, Y | 1 |
| Yaguchi, H | 1 |
| Houzen, H | 1 |
| Kikuchi, K | 2 |
| Hata, D | 1 |
| Ura, S | 1 |
| Takeda, T | 2 |
| Yabe, I | 1 |
| Sasaki, H | 1 |
| Adzić, TN | 1 |
| Stojsić, JM | 1 |
| Radosavljević-Asić, GD | 1 |
| Bouros, D | 1 |
| Kondo, T | 1 |
| Usui, T | 2 |
| Mimori, T | 3 |
| Tomimoto, H | 1 |
| Vernino, S | 1 |
| Takahashi, R | 1 |
| Shi, JH | 1 |
| Liu, HR | 1 |
| Xu, WB | 1 |
| Feng, RE | 1 |
| Zhang, ZH | 1 |
| Tian, XL | 1 |
| Zhu, YJ | 1 |
| Katayama, I | 3 |
| Kotobuki, Y | 1 |
| Kiyohara, E | 1 |
| Murota, H | 1 |
| Möller, J | 1 |
| Girschick, HJ | 1 |
| Hahn, G | 1 |
| Pessler, F | 1 |
| Imbe, H | 1 |
| Ito, T | 1 |
| Kitaoka, H | 1 |
| Ito, S | 2 |
| Kamei, K | 1 |
| Ikoma, M | 1 |
| Shinoda, K | 1 |
| Taki, H | 1 |
| Hounoki, H | 1 |
| Ogawa, R | 1 |
| Tobe, K | 1 |
| Saito, S | 1 |
| Togashi, A | 1 |
| Kaneko, F | 1 |
| Yamamoto, T | 2 |
| Uchida, T | 1 |
| Oyama, N | 1 |
| Efthimiou, P | 1 |
| Kukar, M | 1 |
| Hersh, A | 1 |
| Hasiloglu, ZI | 1 |
| Albayram, S | 1 |
| Tasmali, K | 1 |
| Erer, B | 1 |
| Selcuk, H | 1 |
| Islak, C | 1 |
| Naniwa, T | 1 |
| Takeda, Y | 1 |
| Kamath, V | 1 |
| Prabhakar, B | 1 |
| Lachikarathman, D | 1 |
| Yasuda, K | 1 |
| Sasaki, K | 1 |
| Yamato, M | 1 |
| Hayashi, T | 2 |
| Asashima, H | 1 |
| Inokuma, S | 1 |
| Nakachi, S | 1 |
| Matsuo, Y | 1 |
| Rokutanda, R | 1 |
| Hagiwara, K | 2 |
| Kobayashi, S | 3 |
| Alp, H | 1 |
| Orbak, Z | 1 |
| Erdogan, T | 1 |
| Karabag, K | 1 |
| Gursan, N | 1 |
| Yamamoto, S | 2 |
| Okada, Y | 1 |
| Mori, H | 2 |
| Hirata, S | 1 |
| Saito, K | 1 |
| Inokuchi, N | 1 |
| Tanaka, Y | 1 |
| Wu, TJ | 1 |
| Yan, MT | 1 |
| Chau, T | 1 |
| Lin, SH | 1 |
| Sekiguchi, Y | 1 |
| Shimada, A | 1 |
| Imai, H | 1 |
| Wakabayashi, M | 1 |
| Sugimoto, K | 1 |
| Nakamura, N | 1 |
| Sawada, T | 1 |
| Komatsu, N | 1 |
| Noguchi, M | 1 |
| Gao, LX | 1 |
| Zhang, FC | 1 |
| Wang, L | 1 |
| Zhang, X | 2 |
| Liu, B | 1 |
| Odaka, H | 1 |
| Kiso, K | 1 |
| Watanabe, K | 1 |
| Obata, A | 1 |
| Miyamuma, H | 1 |
| Muryoi, T | 1 |
| Casis, B | 1 |
| Fernández-Vázquez, I | 1 |
| Barnardos, E | 1 |
| Saiz, A | 1 |
| Ballestín, C | 1 |
| Morillas, JD | 1 |
| Colina, F | 1 |
| Solís-Herruzo, JA | 1 |
| Tekeli, O | 1 |
| Ozdemir, O | 1 |
| Martínez-Salio, A | 1 |
| Penas, M | 1 |
| Porta-Etessam, J | 1 |
| Lizasoain, M | 1 |
| Gyulai, R | 1 |
| Kiss, M | 1 |
| Mehravaran, M | 1 |
| Kovács, L | 1 |
| Pokorny, G | 1 |
| Husz, S | 1 |
| Dobozy, A | 1 |
| Arai, C | 1 |
| Furutani, R | 1 |
| Ushiyama, M | 1 |
| Edrees, A | 1 |
| Tran, J | 1 |
| Thompson, G | 1 |
| Watson, KR | 1 |
| Godfrey, W | 1 |
| Abdou, NI | 1 |
| Nagaoka, M | 1 |
| Tamaoki, J | 1 |
| Gotoh, S | 1 |
| Nakazawa, H | 1 |
| Nagai, A | 1 |
| Komatsu, H | 1 |
| Hara, S | 3 |
| Kikuchi, M | 1 |
| Matsumoto, M | 1 |
| Eto, T | 2 |
| Choi, YM | 1 |
| Sheen, DH | 1 |
| Lee, YJ | 1 |
| Lee, EB | 1 |
| Song, YW | 1 |
| Kondo, H | 1 |
| Nakagawa, N | 1 |
| Osanai, S | 1 |
| Ide, H | 1 |
| Nishigaki, Y | 1 |
| Nakano, H | 1 |
| Ohsaki, Y | 1 |
| Tokusashi, Y | 1 |
| Obata, H | 1 |
| Kitagawa, Y | 1 |
| Mitsushima, H | 1 |
| Kawazoe, K | 1 |
| Takahashi, A | 1 |
| Oishi, K | 1 |
| Nagatake, T | 1 |
| Ubara, Y | 1 |
| Sawa, N | 1 |
| Tagami, T | 1 |
| Hosino, J | 1 |
| Yokota, M | 1 |
| Katori, H | 1 |
| Takemoto, F | 1 |
| Takaichi, K | 1 |
| Fujii, A | 1 |
| Murata, H | 1 |
| Nishi, T | 1 |
| Tanaka, H | 2 |
| Abe, T | 2 |
| Nishimura, S | 1 |
| Sakai, H | 1 |
| Kimura, H | 1 |
| Oki, M | 1 |
| Nojima, M | 1 |
| Taga, M | 1 |
| Matsumoto, S | 1 |
| Alchi, B | 1 |
| Sekiguchi, T | 1 |
| Ogino, S | 1 |
| Nishi, S | 1 |
| Ueno, M | 1 |
| Gejyo, F | 1 |
| Sève, P | 1 |
| Poupart, M | 1 |
| Bui-Xuan, C | 1 |
| Charhon, A | 1 |
| Broussolle, C | 1 |
| Muro, Y | 1 |
| Tomita, Y | 1 |
| Togawa, Y | 1 |
| Shinkai, H | 2 |
| Utani, A | 1 |
| Tosun, M | 1 |
| Karkucak, M | 1 |
| Capkin, E | 1 |
| Cakirbay, H | 1 |
| Guler, M | 1 |
| Topbas, M | 1 |
| Azuma, N | 1 |
| Katada, Y | 1 |
| Harada, Y | 1 |
| Arimoto, H | 1 |
| Kimura, Y | 1 |
| Terada, H | 1 |
| Tsujino, K | 1 |
| Kida, H | 1 |
| Kudo, E | 1 |
| Umeshita, M | 1 |
| Mima, T | 1 |
| Saeki, Y | 1 |
| Baba, A | 1 |
| Chen, HA | 1 |
| Lai, SL | 1 |
| Kwang, WK | 1 |
| Liu, JC | 1 |
| Chen, CH | 1 |
| Huang, DF | 1 |
| Sugihara, T | 1 |
| Koike, R | 1 |
| Nosaka, Y | 1 |
| Ogawa, J | 1 |
| Hagiyama, H | 1 |
| Nagasaka, K | 1 |
| Nonomura, Y | 1 |
| Nishio, J | 1 |
| Kohsaka, H | 1 |
| Kubota, T | 1 |
| Miyasaka, N | 1 |
| Nishino, T | 1 |
| Toki, F | 1 |
| Oyama, H | 1 |
| Shimizu, K | 1 |
| Shiratori, K | 1 |
| Sato, T | 1 |
| Oominami, SY | 1 |
| Souma, T | 1 |
| Akiyama, O | 1 |
| Fujii, T | 1 |
| Takeda, N | 1 |
| Ishida, K | 1 |
| Uchihara, T | 1 |
| Mizusawa, H | 1 |
| Yoshida, K | 1 |
| Yokoyama, T | 1 |
| Toyokawa, Y | 1 |
| Yasuda, J | 1 |
| Kingetsu, I | 1 |
| Kurosaka, D | 1 |
| Yamada, A | 1 |
| Mutsukura, K | 1 |
| Ida, H | 2 |
| Furuyama, M | 1 |
| Makino, S | 1 |
| Yonemoto, H | 1 |
| Itoh, S | 1 |
| Takeda, S | 1 |
| Fernandes, M | 1 |
| Vemuganti, GK | 1 |
| Rao, GN | 1 |
| Sumida, T | 2 |
| Shimoyama, K | 1 |
| Ogawa, N | 2 |
| Dei, Y | 1 |
| Suzuki, D | 1 |
| Saito, M | 1 |
| Hayashi, H | 2 |
| Hattori, N | 1 |
| Nakashima, H | 1 |
| Maeda, T | 1 |
| Yanagisawa, K | 1 |
| Nakamaki, T | 1 |
| Tomoyasu, S | 1 |
| Devauchelle-Pensec, V | 1 |
| Pers, JO | 1 |
| Youinou, P | 1 |
| Saraux, A | 1 |
| Yuri, T | 1 |
| Yamazaki, F | 1 |
| Takasu, K | 1 |
| Shikata, N | 1 |
| Tsubura, A | 1 |
| Kobayashi, T | 1 |
| Hatamochi, A | 1 |
| Kamada, N | 1 |
| Matsue, H | 1 |
| Yukawa, S | 1 |
| Tahara, K | 1 |
| Yukawa, N | 1 |
| Shoji, A | 1 |
| Tsuji, S | 1 |
| Tsuboi, N | 1 |
| Tateishi, S | 1 |
| Fukuda, T | 1 |
| Sasaki, M | 1 |
| Koide, Y | 1 |
| Ashizawa, N | 1 |
| Seto, S | 1 |
| Hull, RG | 1 |
| Morgan, SH | 1 |
| Harding, AE | 1 |
| Hughes, GR | 1 |
| Inoh, M | 1 |
| Tokuda, M | 1 |
| Maruoka, T | 1 |
| Kinashi, M | 1 |
| Kurata, N | 1 |
| Okawa, M | 1 |
| Takahara, J | 1 |
| Schnabel, A | 1 |
| Brahma, AK | 1 |
| Hay, E | 1 |
| Sturgess, DA | 1 |
| Morgan, LH | 1 |
| Nishimura, H | 1 |
| Tachibana, H | 1 |
| Makiura, N | 1 |
| Okuda, B | 1 |
| Sugita, M | 1 |
| Ishimaru, S | 1 |
| Izaki, S | 1 |
| Kitamura, K | 1 |
| Morita, Y | 1 |
| Bijl, M | 1 |
| Panders, AK | 1 |
| Vissink, A | 1 |
| Nikkels, PG | 1 |
| Kallenberg, CG | 1 |
| Gerraty, RP | 1 |
| McKelvie, PA | 1 |
| Byrne, E | 1 |
| Kawashima, N | 1 |
| Shindo, R | 1 |
| Kohno, M | 1 |
| Lafforgue, P | 1 |
| Toussirot, E | 1 |
| Billé, F | 1 |
| Acquaviva, PC | 1 |
| Ohtsuka, T | 1 |
| Saito, Y | 1 |
| Hasegawa, M | 1 |
| Tatsuno, M | 1 |
| Takita, S | 1 |
| Arita, M | 1 |
| Okuyama, K | 1 |
| Kashiwabara, K | 1 |
| Kishi, K | 1 |
| Narushima, K | 1 |
| Yagyu, H | 1 |
| Kiguchi, T | 1 |
| Syohda, S | 1 |
| Kusama, H | 1 |
| Matsuoka, K | 1 |
| Sakai, I | 1 |
| Taneichi, K | 1 |
| Shibaki, H | 1 |
| Imasaki, T | 1 |
| Yoshii, A | 1 |
| Tanaka, S | 1 |
| Ogura, T | 1 |
| Ishikawa, A | 1 |
| Steuer, A | 1 |
| McCrea, DJ | 1 |
| Colaco, CB | 1 |
| Matsumura, R | 1 |
| Kagami, M | 1 |
| Tomioka, H | 1 |
| Sugiyama, T | 1 |
| Sueishi, M | 1 |
| Terashima, M | 1 |
| Kageshita, T | 1 |
| Kajiura, Y | 1 |
| Nakata, H | 1 |
| Matsubara, M | 1 |
| Iwai, Y | 1 |
| Yokoyama, M | 1 |
| Yokoyama, A | 1 |
| Konishi, M | 1 |
| Ohosone, Y | 1 |
| Matsumura, M | 1 |
| Oyamada, Y | 1 |
| Yamaguchi, K | 1 |
| Kawahara, Y | 1 |
| Ikeda, Y | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Seino, S | 1 |
| Fukushi, K | 1 |
| Miyata, M | 1 |
| Inuma, H | 1 |
| Kaizuka, M | 1 |
| Tamura, N | 1 |
| Tsunoda, S | 2 |
| Baba, Y | 1 |
| Shirato, K | 1 |
| Onodera, K | 1 |
| Hanada, K | 1 |
| Mochizuki, H | 2 |
| Okano, M | 1 |
| Masaki, T | 3 |
| Nagata, N | 1 |
| Kamakura, K | 2 |
| Hirata, Y | 1 |
| Takizawa, H | 1 |
| Okazaki, H | 1 |
| Yoshida, A | 1 |
| Ishii, A | 1 |
| Kohno, T | 1 |
| Nakajima, J | 1 |
| Oka, T | 1 |
| Ito, K | 1 |
| Tanaka, N | 1 |
| Nakano, T | 1 |
| Isshiki, K | 1 |
| Nagato, Y | 1 |
| Tsujie, M | 1 |
| Nakayama, Y | 1 |
| Kakihara, M | 1 |
| Yamada, Y | 1 |
| Kamata, T | 1 |
| Abe, H | 1 |
| Ohana, M | 1 |
| Okazaki, K | 1 |
| Hajiro, K | 1 |
| Kobashi, Y | 1 |
| Rojas-Rodriguez, J | 1 |
| Garcia-Carrasco, M | 1 |
| Ramirez, ES | 1 |
| Romero-Rodriguez, F | 1 |
| Ramos-Casals, M | 1 |
| Rojas-Serrano, J | 1 |
| Terrazas-Ramirez, A | 1 |
| Hisahara, S | 1 |
| Ohkoshi, N | 1 |
| Shoji, S | 1 |
| Muro, K | 1 |
| Yamaguchi, N | 1 |
| Kobayashi, M | 2 |
| Koyama, A | 1 |
| Usui, K | 1 |
| Anzai, C | 1 |
| Sano, K | 1 |
| Kumazaki, S | 1 |
| Ishihara, T | 1 |
| Yamanouchi, J | 1 |
| Yokota, E | 1 |
| Yamauchi, Y | 2 |
| Matsumoto, I | 1 |
| Kaneko, Y | 1 |
| Suwa, A | 1 |
| Nakajima, A | 1 |
| Ishii, M | 1 |
| Aoki, M | 1 |
| Tsutsumino, M | 1 |
| Goto, M | 1 |
| Uehara, T | 1 |
| Tanaka, K | 1 |
| Inada, S | 1 |
| Izumi, M | 1 |
| Kawabe, Y | 1 |
| Chikazawa, H | 1 |
| Nishiya, K | 1 |
| Hashimoto, K | 1 |
| Onodera, N | 1 |
| Ito, R | 1 |
| Higuchi, A | 1 |
| Suzuki, Y | 2 |
| Monma, N | 1 |
| Waga, S | 1 |
| Tholl, U | 1 |
| Hartung, K | 1 |
| Helmchen, U | 1 |
| Anlauf, M | 1 |
| Yamada, H | 1 |
| Kato, EH | 1 |
| Ebina, Y | 1 |
| Moriwaki, M | 1 |
| Yamamoto, R | 1 |
| Furuta, I | 1 |
| Miyawaki, S | 1 |
| Matoba, K | 1 |
| Peris, P | 1 |
| Font, J | 1 |
| Grau, JM | 1 |
| Martínez de Osaba, MJ | 1 |
| Filella, X | 1 |
| Muñoz-Gómez, J | 1 |
| Katayama, Y | 2 |
| Kohriyama, K | 2 |
| Kirizuka, K | 1 |
| Nishizaki, H | 1 |
| Tanji, Y | 1 |
| Oketani, M | 1 |
| Ideguchi, H | 1 |
| Ohkubo, T | 1 |
| Ohno, S | 2 |
| Shirai, A | 1 |
| Sasaki, T | 1 |
| Nagaoka, S | 1 |
| Ishigatsubo, Y | 1 |
| Koni, I | 1 |
| Kasahara, Y | 1 |
| Yachie, A | 1 |
| Miyawaki, T | 1 |
| Seki, H | 1 |
| Mizukoshi, T | 1 |
| Murakami, R | 1 |
| Tokuno, T | 1 |
| Makiguchi, Y | 1 |
| Ideura, H | 1 |
| Tsukada, Y | 1 |
| Maezawa, A | 1 |
| Ueki, K | 1 |
| Nojima, Y | 1 |
| Naruse, T | 1 |
| Hent, RC | 1 |
| Bergkamp, FJ | 1 |
| Weening, JJ | 1 |
| Schut, NH | 1 |
| Sakurai, M | 1 |
| Hayashi, K | 1 |
| Nemoto, A | 1 |
| Yamauti, M | 1 |
| Morris-Jones, R | 1 |
| Walker, M | 1 |
| Hardman, C | 1 |
| Maeda, A | 1 |
| Yamanouchi, H | 1 |
| Lee, JB | 1 |
| Tanaka, A | 1 |
| Tohda, Y | 1 |
| Fukuoka, M | 1 |
| Nakajima, S | 1 |
| Hayashi, R | 1 |
| Yamashita, N | 1 |
| Maruyama, M | 1 |
| Yoshida, Y | 1 |
| Arai, N | 1 |
| Ishihara, O | 1 |
| Saitoh, M | 1 |
| Hayashi, N | 1 |
| Kinoshita, K | 1 |
| Teruuchi, S | 1 |
| Bando, M | 1 |
| Hironaka, M | 1 |
| Sugiyama, Y | 1 |
| Fukumura, A | 1 |
| Simoyama, K | 1 |
| Karasawa, H | 1 |
| Okada, J | 1 |
| Kim, CG | 1 |
| Wano, Y | 1 |
| Wada, M | 1 |
| Kamimoto, H | 1 |
| Park, SY | 1 |
| Shintani, S | 1 |
| Nakasho, K | 1 |
| Sakamoto, O | 1 |
| Saita, N | 1 |
| Ando, M | 2 |
| Kohrogi, H | 1 |
| Suga, M | 1 |
| Hirata, A | 1 |
| Nakamura, R | 1 |
| Motoyoshi, K | 1 |
| Hermisson, M | 1 |
| Klein, R | 1 |
| Schmidt, F | 1 |
| Weller, M | 1 |
| Küker, W | 1 |
| Pang, M | 1 |
| Setoyama, Y | 1 |
| Tsuzaka, K | 1 |
| Yoshimoto, K | 1 |
| Amano, K | 1 |
| Török, M | 1 |
| Kincses, E | 1 |
| Achenbach, W | 1 |
| Malaviya, AN | 1 |
| Kar, A | 1 |
| Goswami, S | 1 |
| Bhuyan, UN | 1 |
| Kumar, R | 1 |
| Malhotra, KK | 1 |
| Taneja, RL | 1 |
| Nawata, Y | 1 |
| Kato, N | 1 |
| Kawanishi, K | 1 |
| Kawamura, K | 1 |
| Nishina, Y | 1 |
| Goto, A | 1 |
| Okada, S | 1 |
| Saida, K | 1 |
| Bansal, A | 1 |
| Roberts, T | 1 |
| Hay, EM | 1 |
| Kay, R | 1 |
| Pumphrey, RS | 1 |
| Wilson, PB | 1 |
| Nishizaka, Y | 1 |
| Oda, Y | 1 |
| Dohi, K | 1 |
| Morita, H | 1 |
| Funauchi, M | 1 |
| Sugishima, H | 1 |
| Minoda, M | 1 |
| Horiuchi, A | 1 |
| Yamane, K | 1 |
| Shome, GP | 1 |
| Akama, T | 1 |
| Suzuki, H | 1 |
| Matsui, Y | 1 |
| Kashiwagi, H | 1 |
| Nagao, T | 1 |
| Takagi, K | 1 |
| Hashida, H | 1 |
| Sakuta, M | 1 |
| Kamouchi, M | 1 |
| Tsuji, H | 1 |
| Hirakata, H | 1 |
| Okamura, K | 1 |
| Ishitsuka, T | 1 |
| Murai, K | 1 |
| Onoyama, K | 1 |
| Fujishima, M | 1 |
| Heathcote, JG | 1 |
| McCartney, AC | 1 |
| Rice, NS | 1 |
| Peacock, J | 1 |
| Seal, DV | 1 |
| Sato, A | 1 |
| Ida, M | 1 |
| Watanabe, H | 2 |
| Iwata, M | 1 |
| Taniguchi, M | 1 |
| Miyazaki, N | 1 |
| Kido, M | 1 |
| Kajiki, A | 1 |
| Yamazaki, H | 1 |
| Yoashihara, S | 1 |
| Kuroiwa, A | 1 |
| Teramoto, N | 1 |
| Arai, H | 1 |
| Eto, H | 1 |
| Kamimura, K | 1 |
| Uetsuka, M | 1 |
| Kondo, S | 1 |
| Nishioka, K | 1 |
| Yamashita, K | 1 |
| Yamaguchi, S | 1 |
| Tsunematsu, T | 1 |
| Talal, N | 1 |
| Tachibana, J | 1 |
| Yoshioka, R | 1 |
| Sawada, M | 1 |
| Shimizu, S | 1 |
| Hirose, Y | 1 |
| Takiguchi, T | 1 |
| Konda, S | 1 |
| Vasil'ev, VI | 1 |
| Simonova, MV | 1 |
| Safonova, TN | 1 |
| Mach, ES | 1 |
| Ivanova, AV | 1 |
| Bezuglov, MF | 1 |
| Suzuki, T | 1 |
| Yoshida, H | 1 |
| Wakashin, M | 1 |
| Okuda, K | 1 |
| Kawauchi, K | 1 |
| Sugiyama, H | 1 |
| Watanabe, S | 1 |
| Aumaitre, O | 1 |
| Pouplard-Barthelaix, A | 1 |
| Thieblot, P | 1 |
| Dordain, G | 1 |
| Moinade, S | 1 |
| Ho, CH | 1 |
| Chiang, YM | 1 |
| Chong, LL | 1 |
| Lin, HY | 1 |
| Hwang, TS | 1 |
| Job-Deslandre, C | 1 |
| Menkès, CJ | 1 |
| Brunt, MF | 1 |
| James, DG | 1 |
| Williamson, J | 1 |
| Gibson, AA | 1 |
| Wilson, T | 1 |
| Forrester, JV | 1 |
| Whaley, K | 1 |
| Dick, WC | 1 |
| Cziráki, L | 1 |
| Szemere, P | 1 |
| Stacher, A | 1 |
| Böhnel, J | 1 |
| Schindler, H | 1 |
| Seifert, E | 1 |
| Karlish, AJ | 1 |
| Singleton, MA | 1 |
| Gros, JC | 1 |
| Potiakina, NN | 1 |
| Mikanba, ZM | 1 |
| Sage, RE | 1 |
| Forbes, IJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in Patients With Connective Tissue Disease Related Thrombocytopenia (CTD-TP): a Single-arm, Open-label Clinical Trial in China[NCT03688191] | Phase 4 | 20 participants (Anticipated) | Interventional | 2017-09-21 | Active, not recruiting | ||
| A Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects[NCT01316770] | Phase 2 | 14 participants (Actual) | Interventional | 2011-05-01 | Terminated (stopped due to Slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and hel in place by slight negative pressure. Collection time was 1 minute. The outcome measure is looking at change from baseline at Study Day 28 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline to 28 days post-baseline
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | -0.09808 |
| Placebo Irrigation of Parotid Gland | -0.06678 |
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and hel in place by slight negative pressure. Collection time was 1 minute. The outcome measure is looking at change from baseline at Study Day 42 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline to 42 days post-baseline
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | 0.00224 |
| Placebo Irrigation of Parotid Gland | 0.01192 |
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and held in place by slight negative pressure. Collection time was 1 minute. The primary outcome measure is looking at change from baseline at Study Day 56 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline (Study Day 0) to Study Day 56
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | -0.01120 |
| Placebo Irrigation of Parotid Gland | -0.05204 |
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and hel in place by slight negative pressure. Collection time was 1 minute. The outcome measure is looking at change from baseline at Study Day 14 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline to 14 days post-baseline
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | -0.01106 |
| Placebo Irrigation of Parotid Gland | 0.01875 |
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Sip water | Baseline: Sip liquids other than water | Baseline: use commercial products | Baseline: Chew sugared gum or mints | Baseline: Chew sugarless gum or mints | Study Day 14: Sip water | Study Day 14: Sip liquids other than water | Study Day 14: use commercial products | Study Day 14: Chew sugared gum or mints | Study Day 14: Chew sugarless gum or mints | Study Day 28: Sip water | Study Day 28: Sip liquids other than water | Study Day 28: use commercial products | Study Day 28: Chew sugared gum or mints | Study Day 28: Chew sugarless gum or mints | Study Day 42: Sip water | Study Day 42: Sip liquids other than water | Study Day 42: use commercial products | Study Day 42: Chew sugared gum or mints | Study Day 42: Chew sugarless gum or mints | Study Day 56: Sip water | Study Day 56: Sip liquids other than water | Study Day 56: use commercial products | Study Day 56: Chew sugared gum or mints | Study Day 56: Chew sugarless gum or mints | |
| Overall Study | 8 | 6 | 4 | 1 | 2 | 8 | 6 | 3 | 1 | 4 | 8 | 7 | 4 | 2 | 3 | 7 | 5 | 3 | 2 | 3 | 8 | 3 | 3 | 1 | 2 |
Focus score is the number of mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4 mm² glandular section. Table data are the shift in focus score from Stage II Screening to Study Day 56. Only shift table cells with more than 0 participants were included in the Outcome Measure Data Table below. (NCT01316770)
Timeframe: Stage II Screening (within 6 wks before baseline) through 56 days post-baseline
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening Focus=0; Day 56 Focus=0 | Screening Focus=1; Day 56 Focus=1 | Screening Focus=2; Day 56 Focus=0 | Screening Focus=2; Day 56 Focus=5 | Screening Focus=3; Day 56 Focus=not done | Screening Focus=12; Day 56 Focus=3 | Screening Focus=not done; Day 56 Focus=not done | |
| Dexamethasone Irrigation of Parotid Gland | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Placebo Irrigation of Parotid Gland | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
Ordinal Scale 0: least to 10: greatest level of disease activity. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Study Day 14 | Study Day 28 | Study Day 42 | Study Day 56 | |
| Overall Study | 5 | 5 | 5 | 5 | 5 |
Ordinal Scale 0:least to 10:greatest level of disease activity (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Study Day 14 | Study Day 28 | Study Day 42 | Study Day 56 | |
| Overall Study | 5 | 5 | 5 | 5 | 5 |
Focus score is the number of mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4 mm² glandular section. Focus scores ≥1 are key criteria used in the diagnosis of inflammation in the oral component of Sjögren's Syndrome. Higher numbers are associated with more inflammation. (Range 0-12). (NCT01316770)
Timeframe: Stage II screening (within 6 wks before baseline) through 56 days post-baseline
| Intervention | score on a scale (Median) | |
|---|---|---|
| Stage II Screening | Study Day 56 | |
| Dexamethasone Irrigation of Parotid Gland | 2.5 | 1 |
| Placebo Irrigation of Parotid Gland | 1.5 | 0.5 |
Possible Response: Yes or No (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||
| No | Yes | |||||||
| Overall Study | 9 | |||||||
| Overall Study | 0 | |||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on any of the study days. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: Yes | Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 9 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on Study Days 42 and 56. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: No | Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | |||||||||||||
| Overall Study | 7 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 8 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: No | Screening II: Yes; Study Day: Yes | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 3 | |||||||||||||||
| Overall Study | 5 | |||||||||||||||
| Overall Study | 2 | |||||||||||||||
| Overall Study | 6 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 7 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: No | Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | |||||||||||||
| Overall Study | 5 | |||||||||||||||
| Overall Study | 2 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 6 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 3 | |||||||||||||||
| Overall Study | 2 | |||||||||||||||
| Overall Study | 4 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 5 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on any of the study days. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 6 | |||||||||||||||
| Overall Study | 5 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: Yes | Screening II: Yes; Study Day: Yes | Screening II: No; Study Day: No | Screening II: Yes; Study Day: No | |||||||||||||
| Overall Study | 6 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 7 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on any of the study days. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 8 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024068 | Study Day 1472024068 | Study Day 2872024068 | Study Day 4272024068 | Study Day 5672024068 | ||||||
| Yes | No | |||||||||
| All Study Participants | 2 | |||||||||
| All Study Participants | 7 | |||||||||
| All Study Participants | 1 | |||||||||
| All Study Participants | 8 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| Yes | No | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 6 | |||||||||
| Overall Study | 3 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 0 | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 1 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: To little; to much; Do not notice it. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||
| Do not notice it | Too much | Too little | |||||||||||||
| Overall Study | 5 | ||||||||||||||
| Overall Study | 6 | ||||||||||||||
| Overall Study | 0 | ||||||||||||||
| Overall Study | 3 | ||||||||||||||
| Overall Study | 4 | ||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes; No; Not sure. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||
| Yes | No | Not Sure | |||||||||||||
| Overall Study | 3 | ||||||||||||||
| Overall Study | 6 | ||||||||||||||
| Overall Study | 0 | ||||||||||||||
| Overall Study | 1 | ||||||||||||||
| Overall Study | 5 | ||||||||||||||
| Overall Study | 2 | ||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes; No; Not sure. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||
| Yes | No | Not Sure | |||||||||||||
| Overall Study | 6 | ||||||||||||||
| Overall Study | 2 | ||||||||||||||
| Overall Study | 7 | ||||||||||||||
| Overall Study | 8 | ||||||||||||||
| Overall Study | 0 | ||||||||||||||
| Overall Study | 1 | ||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 2 | |||||||||
| Overall Study | 7 | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 0 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||||||||||||
| I have tooth pain | I have gum pain | I have pain in my jaws or TMJ | Mouth or tongue burns | |||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||
| Overall Study | 1 | |||||||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||||||||||||
| Foods taste more intense (for example, more sweet) | Foods taste different than they used to | Foods taste less intense (for example, less sweet) | I have persistent bad taste in my mouth | |||||||||||||||||
| Overall Study | 1 | |||||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| Yes | No | |||||||||
| Overall Study | 3 | |||||||||
| Overall Study | 6 | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 2 | |||||||||
| Overall Study | 7 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 0 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||||||||||
| Dryness | Weakness | Other | Pain | Too few Teeth | |||||||||||||||||||||
| Overall Study | 3 | ||||||||||||||||||||||||
| Overall Study | 1 | ||||||||||||||||||||||||
| Overall Study | 0 | ||||||||||||||||||||||||
| Overall Study | 2 | ||||||||||||||||||||||||
Response: Yes; No (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 7 | |||||||||
| Overall Study | 2 | |||||||||
| Overall Study | 0 | |||||||||
| Overall Study | 9 | |||||||||
Nominal Scale: Much better; Better; The same; Worse; Much worse (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||||||||||
| Better | The same | Much worse | Much better | Worse | |||||||||||||||||||||
| Overall Study | 7 | ||||||||||||||||||||||||
| Overall Study | 2 | ||||||||||||||||||||||||
| Overall Study | 9 | ||||||||||||||||||||||||
| Overall Study | 0 | ||||||||||||||||||||||||
| Overall Study | 1 | ||||||||||||||||||||||||
| Overall Study | 8 | ||||||||||||||||||||||||
Response: Yes or No (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 0 | |||||||||
Nominal scale values: Inactive; Low; Moderate; High (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||||||||||||
| Moderate | Inactive | Low | High | |||||||||||||||||
| Overall Study | 2 | |||||||||||||||||||
| Overall Study | 7 | |||||||||||||||||||
| Overall Study | 3 | |||||||||||||||||||
| Overall Study | 6 | |||||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||
| Overall Study | 4 | |||||||||||||||||||
| Overall Study | 5 | |||||||||||||||||||
Possible response on nominal scale: Inactive; Low; Moderate; High SDAI. (NCT01316770)
Timeframe: Baseline (Study Day 0) to Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Baseline Low to Study Day High | Baseline Moderate to Study Day Inactive | Baseline Moderate to Study Day Low | Baseline Moderate to Study Day Moderate | Baseline Moderate to Study Day High | Baseline High to Study Day Inactive | Baseline High to Study Day Low | Baseline High to Study Day Moderate | Baseline High to Study Day High | Baseline Inactive to Study Day Inactive | Baseline Inactive to Study Day Low | Baseline Inactive to Study Day Moderate | Baseline Inactive to Study Day High | Baseline Low to Study Day Inactive | Baseline Low to Study Day Low | Baseline Low to Study Day Moderate | |||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical evaluations of MRI Scans. Possible evaluations include: i) Normal; ii) Abnormal, not clinically significant; iii) Abnormal, clinically significant. (NCT01316770)
Timeframe: Stage II Screening (within 6 wks before Baseline (Study Day 0)) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening Visit72024065 | Stage II Screening Visit72024066 | Study Day 5672024066 | Study Day 5672024065 | |||||||||
| MRI Normal | MRI Abnormal, not clinically signficant | MRI Abnormal, clinically signficant | ||||||||||
| Dexamethasone Irrigation of Parotid Gland | 5 | |||||||||||
| Placebo Irrigation of Parotid Gland | 5 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 4 | |||||||||||
| Placebo Irrigation of Parotid Gland | 4 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 0 | |||||||||||
| Placebo Irrigation of Parotid Gland | 6 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 3 | |||||||||||
| Placebo Irrigation of Parotid Gland | 3 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 1 | |||||||||||
| Placebo Irrigation of Parotid Gland | 0 | |||||||||||
Medical evaluations of Technetium Scans. Possible evaluations include: i) Normal; and ii) Abnormal. (NCT01316770)
Timeframe: Stage II Screening (within 6 wks before Baseline (Study Day 0)) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stage II Screening Visit72024066 | Stage II Screening Visit72024065 | Study Day 5672024066 | Study Day 5672024065 | |||||
| Normal | Abnormal | |||||||
| Dexamethasone Irrigation of Parotid Gland | 4 | |||||||
| Placebo Irrigation of Parotid Gland | 5 | |||||||
| Dexamethasone Irrigation of Parotid Gland | 5 | |||||||
| Placebo Irrigation of Parotid Gland | 4 | |||||||
18 reviews available for prednisolone and Sicca Syndrome
| Article | Year |
|---|---|
Co-Existence of Sarcoidosis and Sjögren's Syndrome with Hypercalcemia and Renal Involvement: A Case Report and Literature Review.
Topics: Aged; Anti-Inflammatory Agents; Comorbidity; Humans; Hypercalcemia; Male; Prednisolone; Renal Insuff | 2021 |
Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review.
Topics: Antipsychotic Agents; Antirheumatic Agents; Benzodiazepines; Female; Glucocorticoids; Hallucinations | 2014 |
Severe Sensory Neuronopathy in Primary Sjögren Syndrome Resulting in Charcot Arthropathy.
Topics: Aged; Ankle Fractures; Arthropathy, Neurogenic; Electromyography; Female; Follow-Up Studies; Fractur | 2016 |
Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents; Antimalarials; Asian People | 2010 |
Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CD5 An | 2012 |
[A case of Sjögren's syndrome with subacute transverse myelitis as the initial manifestation].
Topics: Anti-Inflammatory Agents; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myelitis, Transvers | 2002 |
[Dementia due to cerebral vasculitis].
Topics: Anti-Inflammatory Agents; Bacterial Infections; Cyclophosphamide; Dementia; Drug Therapy, Combinatio | 2004 |
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, C | 2004 |
[Diagnosis and therapy for Sjogren syndrome].
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Autoimmunity; Biomarkers; Diagnosis, Differential; | 2007 |
Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia.
Topics: Biopsy; Cryptogenic Organizing Pneumonia; Female; Glucocorticoids; Humans; Middle Aged; Muscle, Skel | 1996 |
[Coping with pathological changes in digestive system and kidney in collagen diseases--special reference to Sjogren's syndrome and interstitial nephritis].
Topics: Anti-Inflammatory Agents; Calcium; Female; Humans; Kidney; Middle Aged; Nephritis, Interstitial; Pre | 1996 |
A case of Sjögren's syndrome associated with Sweet's syndrome.
Topics: Acute Kidney Injury; Biopsy, Needle; Glucocorticoids; Humans; Kidney; Male; Middle Aged; Nephritis, | 1997 |
[A case of primary Sjögren's syndrome accompanied by transverse myelitis].
Topics: Anti-Inflammatory Agents; Female; Humans; Middle Aged; Myelitis, Transverse; Peripheral Nervous Syst | 1998 |
Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature.
Topics: Adult; Antibodies, Antinuclear; Autoantigens; Dexamethasone; Echocardiography; Female; Fetal Disease | 1999 |
[Marked improvement by corticosteroid therapy for tumor-forming pancreatitis with Sjögren's syndrome, a case study].
Topics: Anti-Inflammatory Agents; Humans; Male; Middle Aged; Pancreatitis; Prednisolone; Sjogren's Syndrome | 2000 |
[A case of Sjögren's syndrome with pleural effusion].
Topics: Female; Humans; Middle Aged; Pleural Effusion; Prednisolone; Sjogren's Syndrome; Treatment Outcome | 2000 |
[Sjögren's syndrome].
Topics: Antibodies, Antinuclear; Autoimmunity; Cytokines; Diagnosis, Differential; Humans; Prednisolone; Pro | 2000 |
Two cases of Sjögren's syndrome with multiple bullae.
Topics: Aged; Airway Obstruction; Autoimmune Diseases; Blister; Female; Forced Expiratory Volume; Humans; Hy | 2002 |
7 trials available for prednisolone and Sicca Syndrome
| Article | Year |
|---|---|
Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans | 2021 |
[The clinical observation of different therapeutic strategies in combined primary biliary cirrhosis and Sjögren syndrome].
Topics: Adult; Azathioprine; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Prednisolone; Sjog | 2012 |
Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome.
Topics: Adult; Aged; Female; Glucocorticoids; Humans; Middle Aged; Parotid Gland; Prednisolone; Salivation; | 1998 |
Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome.
Topics: Adult; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Pilot Projects; Prednisolone | 1999 |
Disproportion of helper T cell subsets in peripheral blood of patients with primary Sjögren's syndrome.
Topics: Female; Humans; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Prednisolone; Sjogren's Sy | 2000 |
[Comparative evaluation of the treatment of Sjögren's syndrome with anti-rheumatic preparations].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Chlorambucil; Chloroquine; Clinical Trials as Topic; Dr | 1988 |
[Reports on long-term treatments with sintisone (prednisolon-stearoylglycolate)].
Topics: Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Clinical Trials as Topic; Drug Evaluation; Eosinophi | 1974 |
184 other studies available for prednisolone and Sicca Syndrome
| Article | Year |
|---|---|
An Elderly Male with Primary Sjögren's Syndrome Presenting Pleuritis as the Initial Manifestation.
Topics: Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Humans; Male; Pleurisy; Prednisolone; Sjogr | 2021 |
Sjögren's Syndrome Presenting with Temporary Hemiplegia Mimicking Transient Ischemic Attack.
Topics: Cyclophosphamide; Female; Hemiplegia; Humans; Ischemic Attack, Transient; Middle Aged; Prednisolone; | 2022 |
Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Fatigue; Female; Glucocorticoids; Humans; Hydroxychlo | 2019 |
Neuro-Sweet disease in a Japanese woman with Sjögren's syndrome.
Topics: Adrenal Cortex Hormones; Adult; Behcet Syndrome; Diagnosis, Differential; Female; Humans; Meningitis | 2019 |
Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies.
Topics: 5'-Nucleotidase; Adult; Autoantibodies; Azathioprine; CD8-Positive T-Lymphocytes; Female; Haplotypes | 2020 |
Primary Sjogren's syndrome manifesting with distal renal tubular acidosis and severe metabolic bone disease.
Topics: Absorptiometry, Photon; Acidosis, Renal Tubular; Adolescent; Antirheumatic Agents; Arthralgia; Bone | 2020 |
Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer.
Topics: Antineoplastic Agents; Female; Humans; Nivolumab; Pilocarpine; Prednisolone; Salivary Glands; Sjogre | 2020 |
Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
Topics: Adolescent; Child; Cohort Studies; Europe; Female; Glucocorticoids; Humans; Immunosuppressive Agents | 2020 |
Unusual course of generalized lymph node primary plasmacytoma in a patient with Sjögren's syndrome: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2017 |
[Severe Interstitial Lung Disease and Manic Symptoms Secondary to Corticosteroids in a Patient with Systemic Lupus Erythematosus and Secondary Sjögren's Syndrome].
Topics: Bipolar Disorder; Female; Glucocorticoids; Humans; Lung Diseases, Interstitial; Lupus Erythematosus, | 2017 |
Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Autoimmune Diseases; Biomarkers; Bone Density; Bone Den | 2018 |
Primary Sjögren's syndrome with Waldenström's macroglobulinemia presenting as unilateral bloody pleural effusion.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Middle Aged; Pleu | 2017 |
Unresponsiveness to oxytocin due to an extremely thin uterine wall in a pregnant woman with systemic lupus erythematosus and Sjögren's syndrome.
Topics: Adult; Cesarean Section; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Hyster | 2018 |
Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren's syndrome.
Topics: AIRE Protein; Animals; CD4-Positive T-Lymphocytes; Cell Proliferation; Cornea; Disease Models, Anima | 2017 |
Hypertrophic Pachymeningitis in Sjögren's Syndrome.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Hypertrophy; Meningitis; Prednisolone; Sjogren's Sy | 2018 |
Reactivity to anti-RNA polymerase III antibody and nailfold capillary changes in patient with generalized morphea combined with multiple autoimmune disorders.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Capillaries; Female; Hepatitis, Autoimmune; | 2018 |
Emergence of Smoldering ANCA-associated Glomerulonephritis during the Clinical Course of Mixed Connective Tissue Disease and Sjögren's Syndrome.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Female; Glomerulonephritis; Humans; Mixed Connective T | 2018 |
Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report.
Topics: Adult; Castleman Disease; Diagnosis, Differential; Female; Glucocorticoids; Humans; Prednisolone; Sj | 2017 |
A Case of Sjögren's Syndrome Complicated with Interstitial Nephritis and Delayed Onset Autoimmune Hepatitis.
Topics: Acidosis, Renal Tubular; Administration, Oral; Female; Hepatitis, Autoimmune; Humans; Hypokalemia; K | 2018 |
Sjögren's and plasma cell variant Castleman disease: a case report.
Topics: Adult; Anemia, Hemolytic; Castleman Disease; Chlorambucil; Diagnosis, Differential; Drug Therapy, Co | 2018 |
Renal involvement in primary Sjogren's syndrome: a prospective cohort study.
Topics: Acidosis, Renal Tubular; Adult; Asymptomatic Diseases; Biopsy; Case-Control Studies; Female; Glomeru | 2018 |
Autoimmune autonomic ganglionopathy associated with Sjögren's syndrome presenting with recurrent abdominal distension.
Topics: Aged; Autoantibodies; Autoimmune Diseases of the Nervous System; Diagnosis, Differential; Female; Ga | 2018 |
Sjogren's syndrome presenting with hypokalemic periodic paralysis.
Topics: Acidosis, Renal Tubular; Administration, Intravenous; Adult; Antibodies, Antinuclear; Female; Glucoc | 2012 |
[Interdisciplinary approach in a patient with IgG4-associated Mikulicz's disease].
Topics: Anti-Inflammatory Agents; Diagnosis, Differential; Humans; Immunoglobulin G; Male; Middle Aged; Miku | 2013 |
Co-development of autoimmune hepatitis and Sjögren's syndrome triggered by the administration of herbal medicines.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Azathioprine; Bilirubin; Female; Hepatitis, Autoi | 2013 |
SLE and dental erosion: a lethal cocktail.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Female; Fever; Fruit; Human | 2014 |
Autoimmune myelofibrosis accompanied by Sjögren's syndrome in a 47, XXX/46, XX mosaic woman.
Topics: Adult; Chromosomes, Human, X; Female; Follow-Up Studies; Genetic Testing; Glucocorticoids; Humans; P | 2014 |
Interstitial cystitis associated with primary Sjögren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review.
Topics: Adrenal Cortex Hormones; Aged; Cystitis, Interstitial; Drug Therapy, Combination; Female; Humans; Pr | 2016 |
Autoimmune haemolytic anaemia as an initial presentation of primary Sjögren syndrome.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Antirheumatic Agents; Blood Volume; | 2014 |
Organizing pneumonia with atypical computed tomography findings in Sjögren's syndrome.
Topics: Cryptogenic Organizing Pneumonia; Female; Follow-Up Studies; Humans; Middle Aged; Prednisolone; Risk | 2015 |
Corticoid therapy for overlapping syndromes in an HIV-positive patient.
Topics: Adult; Anti-Retroviral Agents; Hepatitis, Autoimmune; HIV Infections; Humans; Male; Polymyositis; Pr | 2015 |
Development of mixed connective tissue disease and Sjögren's syndrome in a patient with trisomy X.
Topics: Adolescent; Antibodies, Antinuclear; Antibodies, Monoclonal, Humanized; Chromosomes, Human, X; Femal | 2015 |
Complication of chronic eosinophilic pneumonia in an elderly patient with Sjögren syndrome.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged, 80 and over; Chronic Disease; Humans; Male; Pre | 2015 |
Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cryptogenic Organizing Pneumonia; Drug Ther | 2015 |
Sjögren's syndrome associated with protein losing gastroenteropathy manifested by intestinal lymphangiectasia successfully treated with prednisolone and hydroxychloroquine.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lymphangi | 2015 |
Prevention of recurrent congenital heart block in a SSA/SSB positive mother using high dose maternal IVIG from 16-week gestation.
Topics: Adult; Antibodies, Antinuclear; Dexamethasone; Female; Glucocorticoids; Heart Block; Humans; Immunog | 2015 |
Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren's syndrome.
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucocortic | 2016 |
Persistent hiccups followed by acute respiratory failure.
Topics: Anti-Inflammatory Agents; Deglutition Disorders; Female; Hiccup; Humans; Prednisolone; Respiratory D | 2016 |
Multiple Mesenteric Panniculitis as a Complication of Sjögren's Syndrome Leading to Ileus.
Topics: Aged; Female; Humans; Ileus; Intestinal Diseases; Mesentery; Panniculitis, Peritoneal; Prednisolone; | 2016 |
Steroid-resistant protein-losing gastroenteropathy complicated with Sjögren's syndrome successfully treated with mizoribine.
Topics: Female; Glucocorticoids; Humans; Immunosuppressive Agents; Middle Aged; Prednisolone; Protein-Losing | 2018 |
Anti-signal recognition particle antibody-positive polymyositis in a patient with Sjögren's syndrome showing various types of annular erythema: Positive correlation between the activities of annular erythema and myositis.
Topics: Arthritis, Rheumatoid; Autoantibodies; Erythema; Humans; Male; Middle Aged; Polymyositis; Prednisolo | 2016 |
Severe Thrombocytopenia as Initial Signs of Primary Sjögren Syndrome in a 9-Year-Old Female.
Topics: Child; Female; Humans; Prednisolone; Sjogren's Syndrome; Thrombocytopenia | 2016 |
Anterior horn syndrome: A rare manifestation of primary Sjögren's syndrome.
Topics: Electromyography; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Methylprednisolone; | 2016 |
Hypokalemic Paralysis in Sjogren's Syndrome Secondary to Renal Tubular Acidosis.
Topics: Acetazolamide; Acidosis, Renal Tubular; Adult; Female; Humans; Hypokalemia; Immunosuppressive Agents | 2016 |
Sensorineural hearing loss as the first manifestation of Sjögren's syndrome.
Topics: Aged; Audiometry; Female; Glucocorticoids; Hearing Loss, Sensorineural; Humans; Prednisolone; Sjogre | 2017 |
[Case of systemic lupus erythematosus occurring after induced abortion and drug eruption].
Topics: Abortion, Induced; Adult; Anticonvulsants; Diagnosis, Differential; Drug Eruptions; Female; Humans; | 2008 |
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Diagnosis, Differential; Female; Glucocorticoids | 2009 |
Bilateral basal ganglia lesions of primary Sjogren syndrome presenting with generalized chorea.
Topics: Aged; Anti-Dyskinesia Agents; Basal Ganglia Diseases; Chorea; Functional Laterality; Glucocorticoids | 2009 |
[Cyclic thrombocytopenia complicated with Sjögren syndrome and the mechanism of periodic platelet count fluctuation].
Topics: Aged; Female; Humans; Immunoglobulin G; Periodicity; Platelet Count; Prednisolone; Purpura, Thromboc | 2008 |
An autopsy case of Sjögren's syndrome with acute encephalomyelopathy.
Topics: Adult; Autopsy; Brain Stem; Central Nervous System Diseases; Female; Humans; Intestinal Pseudo-Obstr | 2008 |
Multinodular pulmonary amyloidosis in primary Sjögren's syndrome.
Topics: Amyloidosis; Biopsy; Female; Glucocorticoids; Humans; Lung Diseases, Interstitial; Middle Aged; Pred | 2008 |
Autoimmune autonomic ganglionopathy with Sjögren's syndrome: significance of ganglionic acetylcholine receptor antibody and therapeutic approach.
Topics: Aged; Antibodies, Antinuclear; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous Syst | 2009 |
Pulmonary manifestations of Sjögren's syndrome.
Topics: Adult; Antirheumatic Agents; Cyclophosphamide; Female; Glucocorticoids; Humans; Lung; Lung Diseases, | 2009 |
[Steroid-induced spinal epidural lipomatosis in pediatric patients].
Topics: Adolescent; Anti-Inflammatory Agents; Arthritis, Juvenile; Child; Drug Therapy, Combination; Epidura | 2010 |
[Neuromyelitis optica in a patient with Sjögren syndrome with distal renal tubular acidosis: case report].
Topics: Acidosis, Renal Tubular; Adult; Aquaporin 4; Autoantibodies; Biomarkers; Female; Humans; Methylpredn | 2010 |
Primary Sjögren syndrome that developed after IgA nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Infla | 2010 |
Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome.
Topics: Adrenal Cortex Hormones; Agglutination; Agglutination Tests; Anemia, Hemolytic, Autoimmune; Autoanti | 2010 |
Primary Sjögren's syndrome with myalgia mimicking dermatomyositis.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Dermatomyositis; E | 2010 |
Rituximab and lupus interstitial lung disease: friend or foe?
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Drug Therapy, Combination; Dysp | 2011 |
A case of primary Sjögren's syndrome presenting primarily with central nervous system vasculitic involvement.
Topics: Adult; Angiography, Digital Subtraction; Azathioprine; Brain; Central Nervous System Diseases; Diagn | 2012 |
Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren's syndrome following immunosuppressive therapy.
Topics: Azathioprine; Female; Heart Failure; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Pred | 2011 |
Sjogren's thrombocytopenia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antihypertensive Agents; Autoimmune Diseases; Female; Humans; | 2011 |
Distal renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Biopsy; Female; Humans; Immunosuppressive Agents; Middle Aged; Nephrocalcin | 2012 |
Extremely high salivary β(2) -microglobulin and Na(+) levels in a Sjögren syndrome patient.
Topics: beta 2-Microglobulin; Female; Glucocorticoids; Humans; Middle Aged; Prednisolone; Saliva; Salivary G | 2012 |
Recurrent parotitis as a first manifestation in a child with primary Sjogren's syndrome.
Topics: Antirheumatic Agents; Child; Diagnosis, Differential; Glucocorticoids; Humans; Male; Methotrexate; P | 2011 |
Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid | 2013 |
Hypokalemic paralysis in a girl with dental and renal calculi. Distal renal tubular acidosis (RTA).
Topics: Acidosis, Renal Tubular; Adolescent; Child; Child, Preschool; Dental Calculus; Dental Restoration, P | 2013 |
[Case of Takayasu's arteritis (type V) together with Sjögrens's syndrome and Basedow's disease].
Topics: Antithyroid Agents; Female; Graves Disease; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome; T | 2002 |
Autoimmune enteropathy in an adult with autoimmune multisystemic involvement.
Topics: Autoantibodies; Autoimmune Diseases; Autoimmunity; CD4-Positive T-Lymphocytes; CD8-Positive T-Lympho | 2002 |
Anterior uveitis and Sjögren's syndrome in a patient with primary biliary cirrhosis.
Topics: Administration, Topical; Drug Therapy, Combination; Female; Humans; Liver Cirrhosis, Biliary; Middle | 2002 |
[Autoimmune meningitis simulating bacterial meningitis].
Topics: Adult; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Autoimmune Diseases; Female; Fever; Hu | 2002 |
Atypical autoimmune blistering dermatosis associated with Sjögren's syndrome.
Topics: Autoantibodies; Autoimmune Diseases; Collagen Type VII; Female; Glucocorticoids; Humans; Middle Aged | 2002 |
Cogan's syndrome presenting as Sjögren's syndrome followed by acute aortic regurgitation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Aortic Valve Insufficiency; Au | 2003 |
[A case of Sjögren syndrome accompanied by interstitial cystitis and interstitial pneumonia improved by suplatast tosilate and prednisolone].
Topics: Aged; Arylsulfonates; Cystitis, Interstitial; Drug Therapy, Combination; Female; Humans; Lung Diseas | 2003 |
[Two cases of interstitial nephritis with primary Sjögren's syndrome successfully treated by steroid therapy].
Topics: Anti-Inflammatory Agents; Female; Humans; Kidney; Middle Aged; Nephritis, Interstitial; Prednisolone | 2003 |
Sjogren's syndrome presenting as remitting seronegative symmetric synovitis with pitting edema (RS3PE).
Topics: Adult; Antibodies, Antinuclear; Arthritis; Biopsy; Blood Sedimentation; Diagnosis, Differential; Ede | 2003 |
Autoimmune aspects of pulmonary hypertension in collagen vascular diseases.
Topics: Connective Tissue Diseases; Glucocorticoids; Humans; Hypertension, Pulmonary; Prednisolone; Sjogren' | 2003 |
Severe pulmonary hypertension associated with primary Sjögren's syndrome.
Topics: Adult; Antigen-Antibody Complex; Complement C1q; Female; Glucocorticoids; Humans; Hypertension, Pulm | 2003 |
[Secondary bronchiolitis obliterans organizing pneumonia with primary Sjögren's syndrome, resulting in acute respiratory distress syndrome: a case report].
Topics: Aged; Cryptogenic Organizing Pneumonia; Fatal Outcome; Female; Humans; Prednisolone; Pulse Therapy, | 2004 |
Severe interstitial cystitis associated with Sjögren's syndrome.
Topics: Cyclosporine; Cystitis, Interstitial; Female; Glucocorticoids; Humans; Hydronephrosis; Immunosuppres | 2004 |
A 70-year-old man with weight loss, dry mouth and renal insufficiency.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Biopsy; Humans; Kidney; Magnetic Resonance Ima | 2004 |
Cricoarytenoid arthritis in Sjögren's syndrome.
Topics: Anti-Inflammatory Agents; Arytenoid Cartilage; Cricoid Cartilage; Female; Humans; Laryngeal Diseases | 2005 |
Anti-ribosomal-P antibodies in a Sjögren syndrome patient associated with lupus erythematosus.
Topics: Adult; Autoantibodies; Biomarkers; Biopsy, Needle; Female; Fluorescent Antibody Technique, Indirect; | 2004 |
Prurigo pigmentosa in a patient with primary biliary cirrhosis and Sjögren syndrome.
Topics: Administration, Oral; Adult; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hyperpigmentation; I | 2004 |
Coexisting ankylosing spondylitis and Sjogren's syndrome: a case report.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non | 2005 |
[Case of primary Sjögren's syndrome with hypereosinophilia and elevation of serum IgE: measurements of serum IL-4, IL-5 and the IgG subclass].
Topics: Eosinophilia; Humans; Hypergammaglobulinemia; Immunoglobulin E; Immunoglobulin G; Interleukin-4; Int | 2005 |
[Three patients with nephrotic syndrome due to membranous nephropathy complicated by Sjögren's syndrome].
Topics: Adult; Anti-Inflammatory Agents; Female; Glomerulonephritis, Membranous; Humans; Liver Cirrhosis, Bi | 2005 |
Middle lobe syndrome as the pulmonary manifestation of primary Sjögren's syndrome.
Topics: Female; Glucocorticoids; Humans; Lung; Middle Aged; Middle Lobe Syndrome; Prednisolone; Radiography; | 2006 |
[Case of subcutaneous and mesenteric acute panniculitis with Sjögren's syndrome].
Topics: Acute Disease; Adult; Female; Humans; Mesentery; Panniculitis; Prednisolone; Sjogren's Syndrome; Sub | 2002 |
Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy.
Topics: Administration, Oral; Aged; Autoimmune Diseases; Biliary Tract; Cholangiopancreatography, Endoscopic | 2006 |
[A case of systemic sclerosis and Sjogren's syndrome with cardiac tamponade due to steroid-responsive pericarditis].
Topics: Aged; Cardiac Tamponade; Female; Humans; Pericarditis; Prednisolone; Scleroderma, Diffuse; Sjogren's | 2006 |
Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Female; Glucocorticoids; Humans; In | 2007 |
Recurrent aseptic meningitis: a new CSF complication of Sjogren's syndrome.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Biomarkers; Chronic Disease; Diagn | 2007 |
Cryofibrinogenemia associated with Sjögren's syndrome: a case of successful treatment with high-dose corticosteroid.
Topics: Adult; Cryoglobulinemia; Cryoglobulins; Dose-Response Relationship, Drug; Drug Administration Schedu | 2007 |
Successful treatment of a patient with primary Sjögren's syndrome complicated with pericarditis during pregnancy.
Topics: Adult; Female; Glucocorticoids; Humans; Pericarditis; Prednisolone; Pregnancy; Pregnancy Complicatio | 2007 |
Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren's syndrome.
Topics: Antibodies, Antinuclear; Female; Glucocorticoids; Heart Block; Humans; Infant, Newborn; Lupus Erythe | 2007 |
Severe pulmonary hypertension in pediatric primary Sjögren syndrome: a case report.
Topics: Antirheumatic Agents; Child; Cyclophosphamide; Female; Humans; Hypertension, Pulmonary; Prednisolone | 2007 |
Bilateral periocular psoriasis: an initial manifestation of acute generalized pustular psoriasis with coexistent Sjögren's syndrome.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adult; Betamethasone; Drug Therapy, Co | 2007 |
A case of proteinase 3-antineutrophil cytoplasmic antibody-positive Sjögren's syndrome complicated with interstitial nephritis.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Female; Humans; Myeloblastin; Nephritis, Interstitial; | 2007 |
[Successful treatment with prednisolone for autoimmune myelofibrosis accompanied with Sjögren syndrome].
Topics: Aged; Autoimmune Diseases; Female; Humans; Prednisolone; Primary Myelofibrosis; Sjogren's Syndrome | 2007 |
[Is rituximab a promising treatment for Sjögren's syndrome?].
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; A | 2008 |
Glomeruloid hemangioma.
Topics: Biomarkers, Tumor; Castleman Disease; Female; Hemangioma; Humans; Lymph Nodes; Middle Aged; Parotid | 2008 |
Systemic lupus erythematosus with lichen planus-like eruptions associated with pericarditis.
Topics: Adult; Diagnosis, Differential; Female; Glucocorticoids; Humans; Lichen Planus; Lupus Erythematosus, | 2008 |
Dramatic regression of mesenteric abnormalities demonstrated on angiography following prednisolone and cyclophosphamide combination therapy in a patient with polyarteritis nodosa associated with Sjögren's syndrome.
Topics: Angiography; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Mesenteric Artery, Superio | 2008 |
A case of mixed connective tissue disease complicated with hypertrophic obstructive cardiomyopathy.
Topics: Anti-Inflammatory Agents; Cardiomyopathy, Hypertrophic; Female; HLA-DR4 Antigen; Humans; Lung Diseas | 2008 |
Sjögren's syndrome presenting as a severe sensory neuropathy including involvement of the trigeminal nerve.
Topics: Adult; Cranial Nerve Diseases; Diagnosis, Differential; Female; Humans; Peripheral Nervous System Di | 1984 |
[Multiple colonic ulcers in a patient with Sjögren's syndrome].
Topics: Adult; Anti-Inflammatory Agents; Colonic Diseases; Female; Humans; Prednisolone; Sjogren's Syndrome; | 1995 |
[The therapy of Sjögren's syndrome].
Topics: Bronchitis; Chronic Disease; Cyclophosphamide; Female; Humans; Methotrexate; Middle Aged; Prednisolo | 1995 |
Acquired Brown's syndrome and primary Sjogren's syndrome.
Topics: Adult; Chloroquine; Diplopia; Female; Humans; Ophthalmoplegia; Prednisolone; Sjogren's Syndrome | 1995 |
Corticosteroid-responsive parkinsonism associated with primary Sjögren's syndrome.
Topics: Aged; Biopsy; Brain; Female; Humans; Magnetic Resonance Imaging; Neurologic Examination; Parkinson D | 1994 |
Neonatal lupus erythematosus: dissolution of atrioventricular block after administration of corticosteroid to the pregnant mother.
Topics: Female; Fetal Diseases; Heart Block; Humans; Infant; Lupus Erythematosus, Cutaneous; Prednisolone; P | 1994 |
[Sjögren's disease].
Topics: Adult; Antibodies, Antinuclear; Female; Humans; Middle Aged; Prednisolone; Rheumatoid Factor; Sialog | 1994 |
Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy.
Topics: Adolescent; Brain; Cyclophosphamide; Female; Humans; Meningoencephalitis; Plasmapheresis; Prednisolo | 1993 |
Primary Sjögren's syndrome with subcortical dementia.
Topics: Brain; Creatine Kinase; Dementia; Electroencephalography; Humans; Magnetic Resonance Imaging; Male; | 1993 |
Astasia-abasia revealing a primary Sjögren's syndrome.
Topics: Brain; Conversion Disorder; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglobulins; M | 1993 |
Central nervous system disease in a child with primary Sjögren syndrome.
Topics: Brain; Child; Diagnosis, Differential; Encephalomyelitis; Female; Hemiplegia; Humans; Immunoglobulin | 1995 |
[Primary Sjögren's syndrome accompanied by pleural effusion].
Topics: Adult; Female; Humans; Pleural Effusion; Prednisolone; Sjogren's Syndrome | 1995 |
[A case of Sjögren's syndrome with lymphocytic interstitial pneumonia].
Topics: Aged; Anti-Inflammatory Agents; Autoantibodies; CD3 Complex; CD4-CD8 Ratio; Female; Humans; Lung Dis | 1996 |
Primary Sjögren's syndrome, ulcerative colitis and selective IgA deficiency.
Topics: Adolescent; Azathioprine; Colitis, Ulcerative; Gastrointestinal Agents; Humans; IgA Deficiency; Immu | 1996 |
[Sjögren's syndrome complicated by thymoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cycloph | 1996 |
Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Antinuclear; Cryoglobulins; Female; H | 1997 |
Mixed-cryoglobulinemia associated with cutaneous vasculitis and pulmonary symptoms.
Topics: Cryoglobulinemia; Dyspnea; Glucocorticoids; Humans; Hypoxia; Male; Middle Aged; Prednisolone; Pulmon | 1997 |
[A case of Sjögren's syndrome with a high titer of anticardiolipin antibody that developed as parkinsonism].
Topics: Antibodies, Anticardiolipin; Azathioprine; Glucocorticoids; Humans; Immunosuppressive Agents; Male; | 1997 |
[Interstitial pneumonia with Sjögren's syndrome: successful treatment with steroids and an immunosuppressant].
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Drug Therapy, Combination; Dyspnea; Female; Humans; I | 1997 |
[Case of remitting seronegative symmetrical synovitis with pitting edema complicated with Sjogren syndrome].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Edema; Fem | 1997 |
Multiple pancreatic masses associated with autoimmunity.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antibodies, Antinuclear; Autoimmune Diseases; Biopsy | 1998 |
Optic neuropathy in a child with primary Sjögren's syndrome.
Topics: Adolescent; Biopsy, Needle; Child; Diagnosis, Differential; Female; Follow-Up Studies; Glucocorticoi | 1998 |
Polymyalgia rheumatica in a patient with acute tubulointerstitial nephritis due to Sjögren's syndrome.
Topics: Aged; Female; Glucocorticoids; Humans; Methylprednisolone; Nephritis, Interstitial; Polymyalgia Rheu | 1998 |
[Primary Sjögren's syndrome with pulmonary hypertension].
Topics: Anemia, Hemolytic; Anti-Inflammatory Agents; Cyclophosphamide; Female; Humans; Hypergammaglobulinemi | 1998 |
[A case of Sjögren's syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy].
Topics: Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Autoimmune Diseases; Bile Duct Diseases; Fe | 1998 |
[Peripheral neuropathy and dysautonomia in a patient with primary Sjögren's syndrome].
Topics: Autonomic Nervous System Diseases; Female; Glucocorticoids; Humans; Hypohidrosis; Hypotension, Ortho | 1998 |
Subclinical Sjögren's syndrome: a significant 67gallium accumulation in the orbits and parotid glands.
Topics: Anti-Inflammatory Agents; Child; Female; Gallium Radioisotopes; Humans; Orbit; Parotid Gland; Predni | 1998 |
[Primary Sjögren's syndrome and glomerulonephritis].
Topics: Aged; Aged, 80 and over; Biopsy; Cyclosporine; Drug Therapy, Combination; Female; Glomerulosclerosis | 1998 |
Calcitriol-mediated hypercalcaemia and increased interleukins in a patient with sarcoid myopathy.
Topics: Antirheumatic Agents; Calcitonin; Calcitriol; Chloroquine; Clodronic Acid; Female; Humans; Hypercalc | 1999 |
Sjögren's syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Cytokines; Female; Glucocorticoids; Hepatit | 2000 |
[A case of Sjögren's syndrome with retrobulbar optic neuritis and cutaneous vasculitis].
Topics: Female; Humans; Middle Aged; Optic Neuritis; Prednisolone; Pulse Therapy, Drug; Purpura; Sjogren's S | 1999 |
Diminished expression of CD59 on activated CD8+ T cells undergoing apoptosis in systemic lupus erythematosus and Sjögren's syndrome.
Topics: Apoptosis; CD59 Antigens; CD8-Positive T-Lymphocytes; Cells, Cultured; Down-Regulation; Humans; Immu | 2000 |
[A male case of Sjögren's syndrome presenting with generalized lymphadenopathy and swelling of both lacrimal and salivary glands which responded remarkably well to an administration of corticosteroids].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Humans; Lacrimal Apparatus; Lymphatic Disea | 2000 |
Sjögren's syndrome and multiple amyloidomas.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Humans; Male; Melphalan; Prednisolone; Sjogren's Syndro | 2000 |
A patient with heat insoluble cryoglobulin.
Topics: Aged; Aged, 80 and over; Cryoglobulinemia; Cryoglobulins; Hot Temperature; Humans; Male; Prednisolon | 2000 |
Multicentric reticulohistiocytosis associated with Sjögren's syndrome.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Female; Histiocytosis, Non-Langerhans-Cell; Humans; | 2000 |
Oral prednisolone improved acetylcholine-induced sweating in Sjögren's syndrome-related anhidrosis.
Topics: Acetylcholine; Administration, Oral; Aged; Female; Glucocorticoids; Humans; Hyperhidrosis; Hypohidro | 2000 |
[A case of primary Sjögren's syndrome with interstitial pneumonia showing bronchiolitis obliterans organizing pneumonia pattern and lymphofollicular formation].
Topics: Administration, Oral; Biopsy; Cryptogenic Organizing Pneumonia; Female; Humans; Lung Diseases, Inter | 2000 |
Successful treatment of embryo implantation failure in patients with the Sjögren syndrome with low-dose prednisolone.
Topics: Adult; Embryo Implantation; Embryo Transfer; Female; Fertilization in Vitro; Glucocorticoids; Humans | 2001 |
[Sjögren's syndrome with multiple bullae and pulmonary nodular amyloidosis].
Topics: Amyloidosis; Antiphospholipid Syndrome; Blister; Bronchiolitis; Diagnosis, Differential; Female; Hum | 2000 |
[A case of Sjögren's syndrome with dermatomyositis who died of rapidly progressive interstitial pneumonia].
Topics: Cyclophosphamide; Cyclosporine; Dermatomyositis; Disease Progression; Fatal Outcome; Female; Humans; | 2001 |
Autoimmune hepatitis concomitant with hypergammaglobulinemic purpura, immune thrombocytopenia, and Sjögren's syndrome.
Topics: Anti-Inflammatory Agents; Female; Hepatitis, Autoimmune; Humans; Hypergammaglobulinemia; Middle Aged | 2001 |
Motor dominant neuropathy in Sjögren's syndrome: report of two cases.
Topics: Aged; Autoimmune Diseases; Biopsy; Diagnosis, Differential; Female; Guillain-Barre Syndrome; Humans; | 2002 |
Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects.
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Biopsy; Humans; Immunosuppressive Agents; Infant; Magn | 2002 |
Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Autoimmunity; Female; Gene Expression Regulation; | 2002 |
[Cellular immunity in Sjögren's syndrom (author's transl)].
Topics: Adult; Antibody Formation; Cell Migration Inhibition; Epitopes; Humans; Immunity, Cellular; Lymphocy | 1977 |
Sjogren's syndrome.
Topics: Cortisone; Humans; Prednisolone; Sjogren's Syndrome | 1978 |
Connective tissue disorders in India II. Clinical and immunological studies in Sjogren's syndrome.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Immunoglobulins; India; Middle Aged; Prednisolone; Sj | 1978 |
[Remarkable effects of adrenal cortex hormone in Sjögren's syndrome].
Topics: Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome | 1978 |
Successful immunosuppressive therapy in insulin resistant diabetes caused by anti-insulin receptor autoantibodies.
Topics: Autoantibodies; C-Peptide; Cyclophosphamide; Diabetes Complications; Diabetes Mellitus; Female; Gluc | 1977 |
[Application of adrenal cortex steroid hormone therapy and the associated problems].
Topics: Churg-Strauss Syndrome; Humans; Paraproteinemias; Peripheral Nervous System Diseases; POEMS Syndrome | 1992 |
Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus.
Topics: Adult; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Female; Humans; Immunoglobulin A; Imm | 1992 |
[A case of systemic lupus erythematosus associated with Sjögren's syndrome diagnosed by lung localization].
Topics: Adult; Female; Humans; Lung; Lupus Erythematosus, Systemic; Prednisolone; Pulmonary Fibrosis; Radiog | 1992 |
[Progress on diagnosis and therapy of kidney diseases complicated with rheumatoid arthritis and Sjogren's syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Humans; Kidney Diseases; Penic | 1992 |
Serum level of interferon-gamma in autoimmune diseases.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antigens, Surface; Arthritis, Rheumatoid; Autoim | 1991 |
Clinical features of patients with mild systemic lupus erythematosus.
Topics: Adolescent; Adult; Autoantigens; Child; Complement C3; Complement C4; Complement Hemolytic Activity | 1991 |
[A case of progressive systemic sclerosis and Sjögren's syndrome complicated by parkinsonism with special reference to the beneficial effect of corticosteroid].
Topics: Aged; Drug Resistance; Female; Humans; Levodopa; Parkinson Disease; Prednisolone; Scleroderma, Syste | 1991 |
Tubulointerstitial disorders in the kidney associated with primary biliary cirrhosis (PBC)
Topics: Female; Humans; Liver Cirrhosis, Biliary; Middle Aged; Nephritis, Interstitial; Prednisolone; Sjogre | 1991 |
Endophthalmitis caused by exogenous nocardial infection in a patient with Sjögren's syndrome.
Topics: Chloramphenicol; Corneal Diseases; Endophthalmitis; Eye Enucleation; Eye Infections, Bacterial; Fema | 1990 |
[Interstitial lung disease in Sjogren's syndrome, MCTD and ankylosing spondylitis].
Topics: Bronchoalveolar Lavage Fluid; Female; Humans; Male; Mixed Connective Tissue Disease; Prednisolone; P | 1990 |
Endobronchial pseudolymphoma associated with Sjögren's syndrome. Report of a case.
Topics: Bronchial Neoplasms; Female; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Prednisolone | 1989 |
Annular erythema: a possible association with primary Sjögren's syndrome.
Topics: Adult; Child; Erythema; Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome; Skin | 1989 |
[A case of primary Sjögren syndrome associated with neurogenic bladder].
Topics: Female; Humans; Methylprednisolone; Middle Aged; Prednisolone; Sjogren's Syndrome; Urinary Bladder, | 1989 |
Sjögren syndrome and pseudolymphoma.
Topics: Autoantibodies; Autoimmune Diseases; Cyclophosphamide; Female; Humans; Lymphoma; Middle Aged; Predni | 1988 |
[Four patients with thrombocytopenia associated with Sjögren's syndrome].
Topics: Adult; Aged; Autoantibodies; Bone Marrow Cells; Female; Humans; Immunoglobulin G; Megakaryocytes; Pl | 1988 |
[Comparative evaluation of various methods of treatment of patients with Sjögren's disease and syndrome at the hospital-polyclinic stages].
Topics: Ambulatory Care; Chloroquine; Dose-Response Relationship, Drug; Hospitalization; Humans; Prednisolon | 1988 |
[Clinical study of autoimmune diseases: recent trends--with special reference to progress in immunological tests and the therapeutic methods. Organ-specific autoimmune diseases. 4) Sjogren's syndrome].
Topics: Autoantibodies; Autoantigens; Drugs, Chinese Herbal; Humans; Immunity, Cellular; Prednisolone; Ribon | 1988 |
Successful treatment of aplastic anemia associated with chronic thyroiditis and Sjögren's syndrome.
Topics: Adult; Anemia, Aplastic; Drug Therapy, Combination; Female; Ferrous Compounds; Humans; Prednisolone; | 1986 |
[Malignant lymphoma associated with Sjögren's syndrome: a case report].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1986 |
[Association of autoimmune dementia, Basedow's disease, and Gougerot-Sjögren syndrome].
Topics: Autoimmune Diseases; Dementia; Graves Disease; Humans; Male; Middle Aged; Prednisolone; Sjogren's Sy | 1985 |
Development of chronic lymphocytic leukaemia in a case of Sjögren's syndrome with systemic lupus erythematosus.
Topics: Aged; B-Lymphocytes; Cephalosporins; Female; Gentamicins; Humans; Leukemia, Lymphoid; Lupus Erythema | 1985 |
[Gougerot-Sjögren syndrome with autoimmune thrombopenia treated with cortisone shocks].
Topics: Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome; Thrombocytopenia | 1985 |
Histology of the lacrimal gland in keratoconjunctivitis sicca.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Female; Humans; Inflammation; Keratoconjunctivitis; Lacrimal Ap | 1973 |
[Successful combined immunosuppressive and corticosteroid therapy of Sjögren's disease].
Topics: Adult; Azathioprine; Chloroquine; Female; Humans; Male; Middle Aged; Prednisolone; Sjogren's Syndrom | 1974 |
[The effect of 6-alpha-fluoro-16-alpha-methyl-1-dehydro-corticosterone (fluocortolone) in internal diseases].
Topics: Acute Disease; Adrenal Insufficiency; Adult; Aged; Arthritis, Rheumatoid; Asthma; Bronchitis; Chroni | 1968 |
Lung changes in Sjögren's syndrome.
Topics: Female; Humans; Lung Diseases; Middle Aged; Prednisolone; Pulmonary Fibrosis; Respiratory Function T | 1969 |
Sialopathies in sarcoidosis.
Topics: Adult; Female; Humans; Hypergammaglobulinemia; Isoniazid; Lacrimal Apparatus; Lymph Nodes; Middle Ag | 1970 |
[Use of prednisolone in Sjögren's syndrome].
Topics: Aged; Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome | 1967 |
A case of multiple autoimmune disease, lymphoid proliferation and hypogammaglobulinaemia.
Topics: Agammaglobulinemia; Aged; Anemia, Hemolytic, Autoimmune; Antibody Formation; Arthritis, Rheumatoid; | 1968 |